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TRANSCRIPTOME-WIDE CHARACTERIZATION OF APOBEC1-CATALYZED 
RNA EDITING EVENTS IN MACROPHAGES  
Claire Ellen Hamilton, Ph.D. 
The Rockefeller University 2014 
 
RNA editing refers to the process by which the sequence of RNA is altered 
through the insertion, deletion or modification of specific nucleotides. Editing of 
mRNA transcripts can increase the informational complexity encoded by the 
genome by producing alternative protein isoforms through specific post-
transcriptional RNA editing events. Additionally, RNA editing in non-coding 
regions of mRNA transcripts has been shown to influence gene expression in a 
tissue-specific manner. In mammals, mRNA editing serves a diverse set of 
biological roles in neuronal function, host defense and lipid metabolism. The 
major mRNA editors acting in mammals include the adenosine deaminases 
acting on RNA (ADARs) and Apolipoprotein B mRNA Editing Catalytic 
polypeptide-1 (APOBEC1).  
 The ADARs and APOBEC1 were originally characterized as catalysts for 
previously characterized biologically important RNA-editing events that resulted 
in specific coding changes; study of additional editing activity was limited by 
standard sequencing techniques. APOBEC1 in particular was characterized in 
the small intestine as mediating a specific editing event in the coding region of 
Apolipoprotein B (Apob). APOBEC1-dependent RNA editing in Apob mediates the 
tissue-specific differential expression of Apob isoforms, a process important for 
intestinal lipid metabolism and transport. The development of next-generation 
sequencing has allowed for transcriptome-wide discovery of RNA editing 
	   	  
activity and has resulted in the identification of more than 10,000 RNA editing 
events, pointing to more biological functions for RNA editing than had been 
previously appreciated.   
 To search for additional APOBEC1 editing events, our lab developed a 
comparative RNA-Seq screen for the transcriptome-wide identification of 
enzyme-specific RNA editing events. Applying this technique to small intestine 
enterocytes, the site of known APOBEC1 activity, we identified over 30 novel 
APOBEC1 editing events in transcript 3’UTRs, which represents the first example 
of physiological APOBEC1 editing outside of the Apob transcript. These newly 
identified editing events were located in evolutionarily conserved regions of 
transcript 3’UTRs, suggesting that this editing activity may have functional 
relevance. The discovery of additional editing activity for APOBEC1, as well as 
the fact that it is expressed in a number of immune cell types, suggests that 
APOBEC1, like other members of the AID/APOBEC family, may contribute to 
cellular immune processes.  
 The focus of the work presented in this thesis is the identification and 
characterization of physiological APOBEC1 editing activity in bone marrow-
derived macrophages (BMDMs). Using a comparative RNA-Seq screen, I 
identified more than 100 novel APOBEC1 editing events in BMDMs. This 
APOBEC1 activity occurred in two distinct editing patterns and fell within 
evolutionarily conserved regions of transcript 3’UTRs. Luciferase reporter assays 
were utilized to assess the consequences of APOBEC1 3’UTR editing on protein 
expression and identified a number of combinations of editing events that affect 
translational outcomes. To determine if APOBEC1 editing could modulate 
protein expression by altering miRNA targeting, high-throughput sequencing of 
	   	  
RNA isolated by cross-linking immunoprecipitation (HITS-CLIP) of the 
Argonaute (Ago) proteins was performed on wild-type and APOBEC1-deficient 
cells. HITS-CLIP yielded transcriptome-wide maps of Ago binding and potential 
miRNA seed regions. While there was considerable overlap between loci 
targeted by both Ago and APOBEC1, little evidence was found for APOBEC1 
disruption or creation of miRNA seed targets. Overall, this work characterizes 
abundant APOBEC1 activity in BMDMs that can modulate protein expression 
levels by a miRNA-independent mechanism. These results point to broader 
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Chapter 1: Introduction  
RNA editing describes the multiple processes by which an RNA sequence 
is altered from that encoded by its DNA, through the insertion, deletion or 
modification of specific nucleotides (reviewed in Gott and Emeson, 2000). The 
term RNA editing was coined in the 1980s specifically to describe the insertion 
and deletion of uridine in the mitochondrial RNA of kinetoplastids (Benne et al., 
1986). This type of RNA editing is termed insertion/deletion editing (reviewed in 
Gott and Emeson, 2000).  
 While the historical definition of RNA editing involves the insertion or 
deletion of mitochondrial nucleotides, the RNA editing field is currently 
predominantly focused on base-modification editing. Unlike uridine 
insertion/deletion editing, base modification occurs in all kingdoms of life and 
functions in a diverse set of biological processes. In base-modification editing, an 
adenosine or cytidine nucleotide is deaminated, resulting in its conversion to a 
substitute base. This reaction is catalyzed by two families of deaminase enzymes: 
adenosine deaminases convert adenosine to inosine (A to I) and cytidine 
deaminases convert cytidine to uridine (C to U). Adenosine and cytidine 
deaminases can act on a diverse set of RNA substrates including tRNAs, mRNAs 
and miRNAs.  
 
1.1 Base-modification editing of tRNAs 
One particularly important form of base modification editing contributes 
to the post-transcriptional modification of tRNAs. Inosine, the product of 
adenosine deamination, can base pair with U, C or A nucleotides. Therefore, the 
introduction of inosine into the first position of the tRNA anticodon (I34) 
1
	   	  
increases the base-pairing flexibility of the tRNA. Along with G:U base-pairing, 
this flexibility is the basis for the “wobble” hypothesis, by which a single tRNA 
can recognize multiple mRNA codons. Editing of tRNA anticodons is a process 
catalyzed by the adenosine deaminases acting on tRNAs (ADATs). In bacteria, 
the adenosine deaminase, TadA/ecADAT2 catalyzes formation of I34 in tRNAArg 
(Wolf et al., 2002). The homologous eukaryotic enzymes, which function as a 
heterodimer of Tad2p/ADAT2 and Tad3p/ADAT3, have a broader specificity 
and act on 7 or 8 tRNA substrates (Gerber and Keller, 1999). These enzymes are 
essential for cell viability in bacteria and yeast, underscoring the importance of 
this specific post-transcriptional modification of tRNA (Gerber and Keller, 1999; 
Wolf et al., 2002).  
The ADATs, although acting on adenosine, have considerable homology 
to cytidine deaminases, particularly in the zinc-dependent deaminase motif 
(Gerber and Keller, 1999). This motif is shared by an entire super-family of 
deaminases that include enzymes that act on free cytosine, cytidine and dCMP as 
well adenosine and cytidine in the context of a polynucleotide. The fact that the 
ZDD is shared by enzymes that can deaminate both C and A, underscores the 
biochemical similarities in the deamination reactions that converts A to I and C 
to U (reviewed in Conticello et al., 2007). Indeed, in trypanosomes, the ADAT2/3 
heterodimer was shown to be capable of catalyzing A-to-I editing in tRNA as 
well as C-to-U editing in a ssDNA substrate (Rubio et al., 2007). The ADATs have 
been proposed to be the evolutionary precursors of the polynucleotide 
deaminases, the ADARs and the AID/APOBEC family (Conticello, 2008; 
Conticello et al., 2007).  
2
	   	  
Although RNA editing also occurs in mitochondrial RNA, tRNA and 
ribosomal RNA, the focus of this work is mRNA editing. Editing events in 
mRNA serve diverse biological functions. Editing of mRNAs can increase genetic 
diversity by altering the genome-encoded transcript sequences, generating 
alternative protein isoforms. Additionally, editing in untranslated regions has 
been proposed to lead to altered gene expression. In higher eukaryotes, mRNA 
editing events are mediated by the adenosine deaminases acting on RNA 
(ADARs) that catalyze adenosine-to-inosine (A-to-I) editing (Figure 1.1), and 
apolipoprotein B-editing enzyme, catalytic polypeptide-1 (APOBEC1), a member 
of the AID/APOBEC family of polynucleotide cytodine deaminases that is 
responsible for cytidine-to-uridine (C-to-U) editing (Figure 1.2). 
 
1.2. Adenosine deaminases acting on RNA: ADARs 
The adenosine deaminases acting on RNA (ADARs) bind to dsRNA 
substrates and catalyze the conversion of adenosine to inosine (reviewed in Bass, 
2002; Keegan et al., 2004; Savva et al., 2012; Valente and Nishikura, 2005). Inosine 
is read as guanosine by translational and reverse transcriptional machinery. A-
to-I editing is the most common editing event in higher eukaryotes, occurring 
predominantly in RNA duplexes formed from inverted Alu or LINE repeats in 
the untranslated regions (UTRs) of primary mRNA transcripts (Athanasiadis et 
al., 2004; Kim et al., 2004; Levanon et al., 2004). The ADARs were first identified 
as dsRNA-unwinding enzymes in Xenopus laevis (Bass and Weintraub, 1987; 
Rebagliati and Melton, 1987) but were redefined shortly thereafter as dsRNA-
editing enzymes (Bass and Weintraub, 1988; Wagner et al., 1989). In mammals, 


























Figure 1.2. The conversion of C-to-U catalyzed by polynucleotide cytidine 
deaminases. 
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terminal deaminase and double-stranded RNA-binding domains. ADAR1 and 
ADAR2 demonstrate deaminase activity (Gerber et al., 1997; Kim et al., 1994; Lai 
et al., 1997; Melcher et al., 1996b), but the function of the catalytically inactive 
ADAR3 remains elusive (Chen et al., 2000; Melcher et al., 1996a). ADAR1 is the 
best-characterized member of this gene family. Two differentially localized 
isoforms of ADAR1 have been identified. The larger form, ADAR1-L or ADAR 
p150, is present in both the cytosol and nucleus and is regulated by an interferon-
inducible promoter (George and Samuel, 1999b; 1999a; Patterson and Samuel, 
1995). The smaller form, ADAR1-S or ADAR1 p110, is exclusive to the nucleus 
and its transcription is driven by two constitutively active promoters (Kawakubo 
and Samuel, 2000). The ADAR proteins are highly conserved in metazoa; two 
ADAR proteins are expressed in C. elegans (Tonkin et al., 2002) while one ADAR 
functions in Drosophila (Palladino et al., 2000). However, while mammalian 
ADARs are essential for life (Higuchi et al., 2000; Wang et al., 2000), ADAR-
deficient Drosophila or C. elegans exhibit significant but non-fatal phenotypes 
(Palladino et al., 2000; Tonkin et al., 2002).  
The domain organization of mammalian ADARs consists of two or three 
amino-terminal dsRNA binding domains (dsRBDs) and a C-terminal catalytic 
zinc-dependent deaminase domain (ZDD). ADAR editing exclusively occurs in 
dsRNA structures and can occur as “selective” editing or “non-selective” editing 
determined largely by the size of the targeted dsRNA duplex. Smaller (15-40 
base-pairs) duplexes promote the deamination of a few “select” adenosines. 
These smaller duplexes, which typically contain additional structural features 
such as bulges, mismatched base-pairs and internal loops (Dawson et al., 2004; 
Lehmann and Bass, 1999), are characteristic of ADAR editing within the coding 
6
	   	  
regions of mRNA targets (Burns et al., 1997; Higuchi et al., 1993; Lomeli et al., 
1994).  
Larger structures (>50 base-pairs) support non-selective deamination 
(Nishikura et al., 1991; Polson and Bass, 1994). This non-selective editing 
predominantly occurs in the untranslated regions of mRNA transcripts, which 
have considerable secondary structure and can form long dsRNA duplexes via 
the pairing of inverted repetitive elements(Athanasiadis et al., 2004; Kawahara 
and Nishikura, 2006; Levanon et al., 2004). Other dsRNA duplexes found in 
ADAR-expressing cells, including viral double-stranded replication 
intermediates and pre-miRNA transcripts (Blow et al., 2006; Kawahara et al., 
2007b), are also well-characterized ADAR targets. Overall, ADARs can act on a 
diverse array of RNA targets and are implicated in many essential biological 
functions.  
The ADAR proteins and APOBEC1 are the only known mammalian 
mRNA editors. Over the last 20 years ADARs have been extensively 
characterized as important for neurological function, hematopoeisis, viral 
immunity and regulation of the interferon response (reviewed in Bass, 2002; 
Hamilton et al., 2010). Furthermore, since the advent of high-throughput 
sequencing technologies, the transcriptomes of ADAR-expressing organisms 
have been extensively deep sequenced, producing extensive sequence data and 
an ever-expanding list of novel RNA editing events in humans (Li et al., 2009b; 
Peng et al., 2012), mice (Cattenoz et al., 2013; Gu et al., 2012) and Drosophilia 
(Hughes et al., 2012; Rodriguez et al., 2012). In contrast, work on APOBEC1 has 
been predominantly focused on intestinal editing. The transcriptome-wide 
editing data has been limited to the work produced by our lab (Rosenberg et al., 
7
	   	  
2011b), identifying 32 novel RNA editing events catalyzed by APOBEC1 in 
intestinal enterocytes.  
ADAR and APOBEC1 editing activities closely resemble one another. Both 
ADAR and APOBEC1 were identified as catalysts of functionally important 
mRNA editing events within the transcript coding regions. Subsequent 
transcriptome-wide sequencing of both enzymes has revealed abundant RNA 
editing within transcript 3’UTRs, with mostly uncertain biological relevance. The 
following sections provide a comprehensive review of ADAR editing in 
mammals including the well-characterized functions of ADAR editing in coding 
regions as well as the more functionally elusive, but extensive, ADAR editing in 
mRNA UTRs.   
 
1.2.1 ADAR editing in the brain 
ADARs are highly expressed in brain tissue and are important for 
neurological function. Site-specific ADAR editing in the brain leads to codon 
changes and thereby protein products with altered physiological functions 
(reviewed in Bass, 2002; Keegan et al., 2004; Valente and Nishikura, 2005). ADAR2 
extensively edits the mRNA of multiple subunits of the glutamate receptor 
(GluR). One A-to-I event, termed the Q/R site, in the GluR-B subunit is essential 
(Higuchi et al., 2000). Upon translation, inosine at this position results in a 
protein with functional differences relative to the non-edited isoform, including 
decreased calcium permeability and altered channel kinetics (Higuchi et al., 1993; 
Lomeli et al., 1994). ADAR2 knockout mice exhibit seizures and premature 
mortality, a phenotype that is rescued by a single nucleotide change at the Q/R 
site of the GluR-B subunit (Higuchi et al., 2000), underscoring the importance of 
8
	   	  
this editing event. ADAR2 editing in the other GluR subunits is less well-
characterized and seems to impart more subtle effects on neurological function 
(reviewed in Bass, 2002).  
In mammals, ADAR editing also modulates the function of the serotonin 
receptor, 5-HT2CR. ADAR-catalyzed editing within the mRNA encoding 5-HT2CR, 
occurs at 5 different sites of the G-protein coupling domain (Burns et al., 1997; 
Niswender et al., 1998). These editing events allow for the expression of multiple 
isoforms of 5-HT2CR with different ligand binding and downstream signaling 
properties. Overall, the ADAR-dependent editing of the serotonin and glutamate 
receptors in the mammalian brain leads the production of multiple protein 
isoforms from one mRNA transcript, resembling APOBEC1 editing of Apob. 
These coding-region editing events underscore how RNA editing can increase 
biological diversity and functional plasticity, a process especially important in 
the brain.  
 
1.2.2. ADAR1 is essential for immune cell development 
Multiple observations demonstrate the importance of A-to-I mRNA 
editing in the immune system, starting with a requirement for ADAR1 in 
immune cell development. More specifically, knockout studies have defined a 
role for ADAR1 in fetal hematopoiesis. ADAR1-deficient mice are known to 
suffer from liver and bone marrow defects and typically die at embryonic day 
11.5–12.5 (Hartner et al., 2004). Using ADAR1 conditional knock-out models, 
Orkin and colleagues have further demonstrated that ADAR1 is necessary for the 
maintenance of both fetal liver-derived and adult bone marrow hematopoietic 
stem cells (HSCs) (Hartner et al., 2009). The authors propose that ADAR1 
9
	   	  
maintains HSC populations by protecting cells from early apoptotic events, 
possibly by regulating interferon signaling pathways (see below). Other recent 
work, however, suggests that ADAR1 activity is essential in the differentiation of 
hematopoietic progenitor cells (HPCs), rather than HSCs (XuFeng et al., 2009). 
Although the question remains as to which stage of hematopoiesis requires 
ADAR1, it is clear ADAR1-deficient precursors do not develop into mature 
immune cells.  
 
1.2.3. ADAR can restrict or enhance viral infection  
As an interferon-inducible gene, it is not surprising that ADAR1 has been 
implicated in antiviral defense. As described above, it appears to be a critical 
regulator of the interferon response, which implies activity on host RNA targets. 
However, as an RNA editing enzyme, ADAR1 could presumably edit viral 
RNAs in a process not unlike APOBEC3-family hypermutation of retroviral 
cDNA. Indeed, like HIV antagonism of APOBEC3G by the Vif protein, vaccinia 
virus and adenovirus have evolved ADAR1 inhibitors that specifically impair 
ADAR1 deaminase activity (Lei et al., 1998; Liu et al., 2001), suggesting an anti-
viral function for ADAR1. ADAR1 does edit a broad spectrum of viral targets but 
seems to play both pro- and anti-viral roles in infection. A-to-I editing has been 
observed in diverse viral RNAs, including influenza virus (Tenoever et al., 2007), 
parainfluenza virus (Murphy et al., 1991), lymphocytic choriomeningitis virus 
(LCMV) (Zahn et al., 2007), vesicular stomatitis virus (VSV) (O'Hara et al., 1984), 
measles virus (Li et al., 2009c; Toth et al., 2009; Wang et al., 2008), polyomavirus 
(Kumar and Carmichael, 1997), hepatitis D virus (HDV) (Luo et al., 1990) and 
hepatitis C virus (HCV) (Taylor et al., 2005). Despite an early recognition of A-to-
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I hyper-editing in viral transcripts during persistent and lytic infections 
(Cattaneo, 1994), the consequences of many of these editing events is still under 
investigation. A clear example of direct ADAR antiviral editing has been 
observed in LCMV RNA transcripts (Zahn et al., 2007). In vitro and in vivo studies 
of LCMV infection demonstrated high rates of ADAR1-specific A-to-I editing 
events, leading to dysfunctional glycoproteins and impaired viral infectivity. In 
addition, recent work on HCV infection identified an ADAR1 editing-dependent 
loss of HCV replicons (Taylor et al., 2005). Replicon loss was thought to be 
attributable to an inosine-specific RNase (Scadden and Smith, 1997; 2001) or to 
viral genome instability introduced by weakly base-pairing inosine nucleotides 
(Taylor et al., 2005). ADAR family members can also directly restrict viral 
replication independent of its editing function. ADAR1 associates with and 
activates transcription factors involved in anti-viral gene expression, including 
nuclear factor 90 (NF90) (Nie et al., 2005). ADAR1 interacts with NF90 via an 
undefined dsRNA bridge and leads to the upregulation of NF90-regulated genes, 
including IFN!.  
In contrast to these well-characterized anti-viral functions, ADAR proteins 
can also promote viral infection and replication. A recent screen for effectors of 
the type I interferon response identified ADAR as a pan-viral stimulatory factor; 
ADAR enhanced the replication of numerous viruses including HCV, yellow-
fever virus, West Nile virus and HIV-1 (Schoggins et al., 2011). While p110 
ADAR1 is the predominant isoform during embryogenesis (George et al., 2005), 
the p150 interferon-inducible form is more prevalent in hematopoietic stem cells 
of the adult (Hartner et al., 2004). Expanding on their work with the conditional 
knockout mice, Orkin and colleagues showed that ADAR1 acts as novel 
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suppressor of the type I interferon response. Specifically, gene signatures of 
uninfected ADAR1-deficient HSCs and erythroid precursors are highly similar to 
those of virus-infected or interferon-treated cells. Additionally, ADAR1 knockout 
embryos were found to have significantly higher levels of type 1 interferon in 
extracellular fluid. It remains to be explained how ADAR1 dampens the 
interferon response in the absence of viral infection. ADAR1 could be editing a 
microRNA molecule or target, neutralizing an unidentified immunostimulatory 
dsRNA or functioning in the regulation of interferon-induced gene expression. 
An intriguing hypothesis is that ADAR1 functions as a cytosolic dsRNA binding 
protein competing for substrates with the DNA-dependent activator of interferon 
regulatory factors (DAI). In sequestering immunostimulatory dsRNA (such as 
viral replication intermediates) from DAI, ADAR1 may impair downstream 
innate immune signaling (Wang et al., 2008). The absence of ADAR1 dsRNA 
binding activity could lead to aberrant activation of the innate immune response 
and a corresponding induction of interferon production.  
Perhaps related to its role in regulation of the interferon response, ADAR1 
has been observed to bind and impair host antiviral response elements. Work on 
measles viral infection has shown ADAR1 inhibition of protein kinase regulated 
by RNA (PKR) and interferon regulatory transcription factor-3 (IRF-3) (Toth et 
al., 2009). Other groups have observed similar ADAR1 regulation of PKR during 
infections by VSV (Li et al., 2009c; Nie et al., 2007) and HIV (see below) as well. 
Inhibition of these proteins compromises the host cell’s ability to respond to viral 
signals, potentially promoting persistent infection. Interestingly, hyper-editing of 
viral transcripts has been observed in patients suffering from a complication of 
persistent measles infection. This paradoxical situation, in which there is 
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evidence of ADAR1 activity both supporting and antagonizing viral infection 
suggests a nuanced role for ADAR1 in host-virus interaction. It appears that 
ADAR1 can dampen type I interferon signaling by several mechanisms. This 
function may have evolved to protect the host from an inappropriate (i.e., in 
uninfected cells) or overactive (i.e., disproportionate response to infection) 
interferon response. This regulation might serve to counterbalance the effector 
functions of ADAR1 as an antiviral enzyme. However, it seems that in certain 
infections, ADAR1 anti-viral activity is not only impaired but the enzyme itself 
may be co-opted by viruses to support infection. In this context, the significance 
of ADAR1 hyper-editing viral RNA remains unclear.  
Like its deaminase cousin APOBEC3G, ADAR1 has recently been found to 
target and edit HIV-1 sequences. However, unlike APOBEC3G, which edits 
retrotranscript cDNA and restricts viral infection, ADAR1 targets viral RNA and 
enhances HIV protein expression, replication and infectivity (Doria et al., 2009). 
These effects are mediated by both editing-dependent and editing-independent 
mechanisms. Over-expression of ADAR1 in HIV-1 producer cells dramatically 
enhances expression of several viral proteins irrespective of RNA editing, 
possibly due to ADAR inhibition of PKR (Clerzius et al., 2009). Active RNA 
editing may also regulate virus production as ADAR1, but not experimentally-
engineered catalytic mutants, increased the release of progeny virions 2-fold and 
enhanced HIV-1 infectivity 2.5-fold (Doria et al., 2009). Further investigation is 
needed to understand the regulation, impact and mechanism of ADAR1 editing 
in HIV-1 RNA.  
The best-characterized ADAR-mediated viral editing event occurs during 
HDV infection. HDV is a subviral pathogen that is dependent on a concurrent 
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infection with HBV; it requires HBV surface antigen to infect hepatocytes (Lai, 
1995; Taylor, 2003). The genome of HDV is an ideal substrate for ADARs, as its 
single-stranded negative sense circular RNA forms secondary structures with 
frequent duplex regions (Wang et al., 1986). In addition to co-opting the hepatitis 
B surface antigen, the HDV genome encodes its own HDV-specific surface 
antigen (HDVAg), the antigenome transcript of which is edited by ADAR1 in a 
site-specific manner (Casey and Gerin, 1995; Luo et al., 1990; Polson et al., 1996). 
The HDVAg occurs in two forms, both essential for the viral life cycle. The short 
form, HDVAg-S is required for viral RNA replication (Kuo et al., 1989) while the 
long form (HDVAg-L) directs viral genome assembly and packaging (Chang et 
al., 1991; Ryu et al., 1992). ADAR1 targets the HDV antigenome at a specific 
“amber/W site,” thereby converting a stop codon (UAG) to a tryptophan (UIG). 
This allows for the translation of the long form of the HDV surface antigen 
(Casey and Gerin, 1995; Luo et al., 1990; Polson et al., 1996). The HDVAg-L then 
restricts viral replication in a trans-dominant fashion by binding HDAg-S and 
interrupting HDAg-S homodimers (Chao et al., 1990; Glenn and White, 1991). In 
unstimulated cells, amber/W site editing occurs via the ADAR1-S isoform (Jayan 
and Casey, 2002; Wong and Lazinski, 2002) and serves to support viral assembly; 
HDVAg-L halts replication and mediates viral packaging by binding clathrin 
heavy chain (Huang et al., 2009). However, more recent studies have shown that 
ADAR1 can serve an anti-viral role when editing in a more promiscuous fashion. 
Over-expression of ADAR1 or ADAR2 (though ADAR2 is not induced in natural 
infection) leads to hyper-editing at non-amber/W sites, producing higher levels 
of HDAg-L as well as other HDAg mutants that can also bind HDAg-S and 
inhibit replication. In an interferon-stimulated system, which more closely 
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mimics both early natural infection (Hartwig et al., 2004) and IFN-treated 
infection, the large form of ADAR1 is highly expressed, is the predominant 
editor, and increases editing 2-fold (Hartwig et al., 2006). It is unclear, however, 
whether IFN stimulation would induce high enough levels of ADAR1-L to edit 
promiscuously or to significantly impair viral replication. In fact, while a 
replication-competent mutant virus with enhanced editing at the amber/W site 
displays increased levels of HDAg-L early in infection and impaired replication 
at a later time point, editing and replication seem to be coupled (Sato et al., 2004). 
Amber/W site editing ceases with replication, indicating a natural feedback 
mechanism controlling aberrant editing by elevated ADAR1 activity. 
 
1.2.4 ADAR editing and oncogenesis  
 As ADARs directly alter nucleotide sequences, it has been speculated that 
ADAR-catalyzed RNA editing could promote oncogenesis. There is some 
indirect evidence to support this, including altered editing profiles in tumor 
specimens, especially editing found in transcripts encoding tumor suppressors 
(reviewed in Skarda et al., 2009). Recently ADAR-catalyzed A-to-I editing was 
directly implicated in hepatocellular carcinoma (HCC), centered on increased A-
to-I editing in the antizyme inhibitor 1 (Azin1) transcript observed in a 
substantial set of human HCC specimens (Chen et al., 2013). The elevated editing 
in Azin1 led to a gain-of-function phenotype in the encoded protein, increasing 
its stability and allowing it to bind with greater affinity to antizyme. Antizyme 
typically functions to target growth-promoting proteins for degradation. 
Therefore by restricting the inhibitory activity of antizyme, edited AZIN1 
promoted cell proliferation and tumor progression. This work is the first well-
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characterized direct link between ADAR editing and oncogenesis and points to 
further functions for RNA editing in promoting cellular transformation.  
 
1.2.5 ADAR editing in untranslated regions  
In addition to the ADAR coding targets essential to neurological function, 
a few additional editing events within the translated regions of mRNA have been 
characterized (Levanon et al., 2005; Riedmann et al., 2008), but the overwhelming 
majority occur in untranslated regions (UTRs) of transcripts, introns or miRNA 
processing intermediates. Most of this untranslated editing occurs within Alu or 
LINE repeats, which through intramolecular base-pairing of inverted repeats, 
form long RNA duplexes ideal for extensive ADAR editing (Athanasiadis et al., 
2004; Blow, 2004; Kim et al., 2004; Li et al., 2009b). Alu elements are ~300nt 
repetitive transposable elements which make up ~10% of the human genome, 
occurring primarily in the UTRs or introns of transcribed mRNAs (Lander et al., 
2001). Alu elements can contain cryptic splice sites and can occasionally 
aberrantly incorporate into mature transcripts, a process termed exonization, 
posing a threat to transcriptome integrity. In one example, intronic ADAR 
editing in an Alu element prevented its exonization into the mature mRNA 
(Sakurai et al., 2010). However, the functional consequences for most of these A-
to-I editing events within Alu regions remain elusive, although they have been 
proposed to modulate gene expression. Specifically, examples of ADAR editing 
have been found to induce nuclear retention of the edited transcript, target the 
transcript for cleavage, and abolish or create miRNA target sites.  
Nuclear retention of inosine-containing transcripts occurs via association 
with a nuclear inosine-specific RNA binding protein p54nrb that sequesters these 
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mRNAs in nuclear paraspeckles (Chen and Carmichael, 2009; Prasanth et al., 
2005; Zhang and Carmichael, 2001). In an experimental system, introduction of 
inverted Alu elements into a GFP gene resulted in dramatic nuclear retention via 
ADAR editing and binding to p54nrb, underscoring the potential importance of 
this method of Alu and ADAR-mediated gene silencing (Chen et al., 2008). 
However, highly edited endogenous cytoplasmic mRNA transcripts have been 
identified, suggesting that nuclear retention may not be the fate of all ADAR-
targets (Chen and Carmichael, 2009; Chen et al., 2008; Hundley et al., 2008). 
Furthermore, p54rnb binding does not require inosines, suggesting that an 
additional feature may be targeting identified inosine-containing transcripts to 
the nucleus.  
Additional inosine-containing mRNA transcripts are targeted for mRNA 
cleavage by a specific nuclease. In vitro work suggests that Tudor Staphylococcal 
nuclease (Tudor-SN) binds stretches of I:U base-pairs and promotes the cleavage 
of the hyper-edited transcripts (Scadden, 2005), either through its own nuclease 
activity (Yang et al., 2006) or by another unidentified factor (Scadden, 2005). 
Although other endogenous inosine-containing mRNAs are shown to be cleaved 
upon stress conditions (Prasanth et al., 2005), the Tudor-SN cleavage mechanism 
has not been established in vivo.  
ADAR editing events have been shown to modulate miRNA silencing by 
editing of miRNA targets and double-stranded nuclear precursors. As ADAR 
editing predominantly occurs in conserved regions of 3’UTRs, it was postulated 
that ADAR editing could create or disrupt miRNA target sequences (Liang and 
Landweber, 2007). A few examples of ADAR editing creating miRNA seed 
targets have been characterized, but few disruptions could be identified 
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(Borchert et al., 2009). Other work additionally demonstrates that miRNA 
targeting is rare in Alu repeats, suggesting that overlap between ADAR editing 
and miRNA targeting machinery may be limited (Hoffman et al., 2013).  
Precursor miRNAs (pri-miRNAs and pre-miRNAs) can also be edited by 
ADARs, where introduction of I:U mismatches disrupts miRNA processing 
(Kawahara et al., 2008; 2007a; Yang et al., 2006) or changes the targeting 
specificity of the mature miRNA (Kawahara et al., 2007b). In one well-
characterized example, ADAR editing in the seed region of pri-miR-376 endowed 
the mature miRNA product with distinct binding properties, allowing the edited 
form to target an alternative transcript (Kawahara et al., 2007b). High-
throughput miRNA sequencing has shown that this ADAR-catalyzed pri-
miRNA editing does occur somewhat frequently (Alon et al., 2012; Vesely et al., 
2012), and that some edited miRNAs are differentially expressed in ADAR-
deficient embryos (Vesely et al., 2012). Intriguingly, very recent work 
demonstrated that ADAR promoted miRNA processing by a protein-protein 
association with DICER (Ota et al., 2013). The potential importance of this 
process is supported by Adar-/- embryos, which exhibit a global inhibition of 
miRNA expression and subsequent upregulation of targeted transcripts (Ota et 
al., 2013), suggesting that ADAR editing-independent modulation of DICER has 
as profound effect on global miRNA expression.  
Other in vitro experiments have additionally demonstrated that ADAR can 
compete with DICER for dsRNA substrates as part of siRNA gene silencing 
(Knight and Bass, 2002; Scadden and Smith, 2001). This work has primarily been 
observed in C. elegans and Drosophila knock-down experiments, but taken 
together with the catastrophic phenotype for ADAR1-null mice discussed above, 
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could point to an essential function for ADAR in suppressing potentially 
immunostimulatory dsRNA. All together, this work firmly suggests a role for 
ADAR editing in small RNAs, primarily in miRNA processing through both 
editing and editing-independent mechanisms.  
 
1.3. Polynucleotide cytidine deaminases: the AID/APOBEC family 
The AID/APOBEC family of zinc-dependent polynucleotide cytidine 
deaminases catalyze the conversion of cytidine to uridine in a strand of DNA or 
RNA, effectively altering the sequence of the targeted polynucleotide. The family 
was named for its founding member Apolipoprotein B mRNA Editing Catalytic 
polypeptide-1 (APOBEC1), identified as the catalyst for a well-characterized C-
to-U editing event in the mRNA transcript of apolipoprotein B. The other family 
members include Activation-induced cytidine deaminase (AID), APOBEC2, the 
subfamily of APOBEC3 (A-H) enzymes and the computationally predicted 
APOBEC4. AID/APOBEC deaminases all share a characteristic zinc dependent 
deaminase domain (ZDD). In the ZDD three conserved residues, two cysteines 
and a histdine, coordinate a zinc atom to activate a water molecule for hydrolytic 
cytidine deamination. Additional conserved glutamic acid and proline residues 
in the active site also play an essential role in the reaction, transferring a proton 
from the water molecule to the imino in the pyrimidine ring and ensuring the 
conformational integrity of the catalytic pocket, respectively (reviewed in Smith, 
2009). APOBEC1 was originally identified as a cytidine deaminase based on 
homology to zinc-dependent cytidine deaminases in yeast and E. coli, which act 
on a monomeric substrates as a part of the pyrimidine salvage pathway 
(Navaratnam et al., 1995; 1993). While the members of the AID/APOBEC family 
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share significant homology with these enzymes, particularly in the ZDD, they 
appear to act only on single-stranded polynucleotide substrates.  
  In contrast to the ancient family of cytidine deaminases acting on free 
cytidine found in all kingdoms of life, the AID/APOBEC family is a later 
evolutionary development and is restricted to the vertebrate lineage (Conticello 
et al., 2005). AID is thought to be the ancestral member of this protein family, 
which arose concurrently with vertebrates and the development of adaptive 
immunity. AID, APOBEC2, and APOBEC4 are all present in jawed vertebrates 
(Conticello et al., 2005). Phylogenetic analyses indicate that APOBEC4 may have 
evolved independently from AID but APOBEC2 is likely to have arisen by 
duplication of the AID locus (Conticello, 2008). APOBEC1 and APOBEC3 are 
derived from more recent AID gene duplication events and are restricted to 
mammals and placental mammals, respectively (Conticello et al., 2005). 
APOBEC3, a single locus in the mouse, has undergone a dramatic expansion 
process in primates into an array of 8 Apobec3 genes encoding APOBEC3A-H. 
The emergence of this APOBEC3 subfamily is most likely due to extensive 
selective pressure by the rapid evolution of its target retroviruses and 
retrotransposons (Sawyer et al., 2004).  
 Throughout primate evolution, the majority of the AID/APOBEC 
enzymes have evolved rapidly, displaying some of the strongest signals of 
positive selection in the human genome (Sawyer et al., 2004), an evolutionary 
pattern associated with host defense. Indeed, while members of AID/APOBEC 
family are implicated in a diverse set of biological processes, the majority 
function in immunity. AID drives antibody diversification in B cells through the 
processes of somatic hypermutation and class switch recombination. The 
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APOBEC3 subfamily acts directly on endogenous viral retrogenomes and 
restricts exogenous retroviral production. APOBEC2 and APOBEC4 are 
“orphan” deaminases with no well-established targets. The well-characterized 
function for APOBEC1, the subject of this discussion, is in lipid absorption and 
transport in the small intestine. However, the evolutionary history of the 
AID/APOBEC family and APOBEC1’s wide expression in immune cells suggest 
that this enzyme may have previously unappreciated roles in the immune 
system. The following sections will give a general overview of the biological 
functions of the members of the AID/APOBEC family of cytidine deaminases, 
concluding with a detailed discussion of the known activity of APOBEC1 and the 
growing evidence for its function beyond the intestine.  
 
1.3.1. Activation-induced cytidine deaminase: AID  
 AID is a key player in antibody-mediated adaptive immunity, mediating 
secondary antibody diversification through somatic hypermutation (SHM) and 
class-switch recombination (CSR) (Figure 1.3). In the decade since AID was 
identified, AID’s role in SHM and CSR has been extensively characterized 
(reviewed in Delker et al., 2009). In SHM, AID introduces point mutations in the 
recombined variable region of the immunoglobulin locus in germinal center B 
cells. These mutations are removed by uracil DNA glycosylase (UNG) and then 
repaired through the activities of error-prone base excision repair (BER) and 
mismatch repair (MMR) enzymes (Figure 1.3). The combined high editing rate of 
AID and error rate of these enzymes leads to the rapid introduction of genomic 
mutations in immunoglobulin (Ig) loci, some of which alter the affinity of the 
encoded antibody. B cells with improved antigen binding affinity are positivity 
21
(A)       Somatic Hypermutation




S       C    C          S 3  C 3      S 1 C 1       S 2b C 2b     S 2a C 2a        S   C            S   CVDJ
VDJ             S        C    C         S 3  C 3         S 1 C 1      
     S 1  C    1VDJ
transcription/translation













Figure 1.3. AID drives antibody diversity through two distinct mechanisms. 
(A) In SHM, AID deaminates cytidines within the variable region of Ig loci. 
Genomic deoxyuridine residues are then resolved by two pathways. Uridine is 
read as thymidine by replication machinery, leading to transition mutations. 
Alternatively, UNG excises the edited base, which is followed by abasic site 
repair via base-excision repair and mismatch-repair enzymes, leading to 
transversion mutations. (B) In CSR, AID deaminates cytidines within Ig switch 
(S) regions, leading to double strand breaks. Recombination replaces the 
primary constant switch region (Cµ) with one of several downstream constant 
regions (Cγ, Cε or Cα), altering the effector properties of the encoded antibody. In 
this representation, the primary Cµ region is replaced with a Cγ1 region, thereby 
causing a switch from the IgM to the IgG1 isotype.
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selected for, and cycles of mutation and selection lead to an optimized pool of B 
cells capable of initiating a highly specific immune response against a particular 
invading pathogen. In CSR, AID editing in the switch regions of the Igh locus 
mediates the formation of double-stranded breaks that lead to a recombination 
event, replacing the primary constant region with an alternative downstream 
constant region. These constant regions encode the Fc region of the antibody, 
which determines the isotype. Prior to class switch, all B cells express IgM; 
recombination events lead to the production of secondary isotypes (IgA, IgE, and 
IgGs in mammals). The processes of SHM and CSR are entirely dependent on 
AID; Aicda-/-- B cells express no secondary antibody isotypes and have no 
apparent somatic mutation in the variable region of the Ig loci (Muramatsu et al., 
2000). In humans, loss-of-function mutations in the gene encoding AID results in 
a comparable deficiency, termed hyper-IgM syndrome 2 (Revy et al., 2000).  
At its discovery, AID was proposed to function as an RNA editing 
enzyme because of its homology to APOBEC1 (Muramatsu et al., 1999). The 
subsequently developed “RNA-editing hypothesis” of AID function in SHM and 
CSR suggests that to mediate both processes AID edits the mRNAs of auxiliary 
factors. This proposal also reflected the APOBEC1 editing model, as it required 
the assistance of additional co-factors, resembling the relationship between 
APOBEC1 and its “editosome.” The alternative “DNA-editing hypothesis” 
proposed that AID itself was directly mutating the Ig loci, triggering SHM and 
CSR. The processes of SHM and CSR described above reflect the predominantly 
accepted AID DNA-editing model, but the RNA editing hypothesis has not been 
entirely discarded (Shivarov et al., 2009).  
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A large body of work has demonstrated the direct DNA editing capacity 
of AID in support of the DNA editing hypothesis. Endogenous AID is found to 
be directly bound to the Ig locus in activated splenic B cells (Vuong et al., 2009; 
Yamane et al., 2011) and ectopically expressed AID is capable of inducing DNA 
mutations in a diverse set of cell types, including both prokaryotic and 
eukaryotic cells (Martin and Scharff, 2002; Mayorov et al., 2005; Petersen-Mahrt 
et al., 2002; Poltoratsky et al., 2004; Yoshikawa et al., 2002). Furthermore, while 
AID can bind both RNA and DNA in vitro (Dickerson et al., 2003; Nonaka et al., 
2009), editing assays demonstrated that AID is only capable of deaminase 
activity on a DNA substrate (Besmer et al., 2006; Bransteitter et al., 2003; 
Chaudhuri et al., 2003). These in vitro studies additionally demonstrated that AID 
prefers to edit WRC ([A or T][A or G]C) motifs (Pham et al., 2003; Yu et al., 
2004a), a pattern also observed in SHM editing of the Ig locus (Rogozin and Diaz, 
2004). Finally, deep sequencing of the B cell transcriptome failed to identify any 
bona fide AID-mediated RNA editing events (Fritz et al., 2013). Additional 
support for the DNA-editing hypothesis was provided by the analysis of mice 
deficient in UNG, the glycosylase that cleaves mismatched uridines introduced 
by C-to-U editing. These animals exhibited an altered array of mutations in the Ig 
locus as compared to their wild-type littermates, with a bias toward C-to-T and 
G-to-A mutations (Rada et al., 2002). This suggests that the initiating event in 
SHM is a C-to-U conversion catalyzed by a cytidine deaminase. Error-prone 
repair of these mismatches, catalyzed by UNG and the base-excision and 
mismatch repair pathways, leads to accumulation of other transition and 
transversion mutations, pointing to the importance of both AID and the DNA 
repair enzymes in SHM. Taken together, this work strongly suggests that the 
24
	   	  
“RNA-editing hypothesis” is false and demonstrates that the predominant 
substrate for AID is ssDNA.  
As AID activity can mutate genomic DNA and introduce double-stranded 
breaks, aberrant AID activity has great oncogenic potential. To combat 
deleterious off-target mutations, while preserving essential immunological 
function, the transcription, translation, cellular localization and targeting of AID 
are tightly regulated (reviewed in Delker et al., 2009). The many modes of AID 
regulation are still under intensive investigation and are largely beyond the 
scope of this discussion. Below, I will briefly expand on the regulation of AID by 
miRNAs, post-translational modifications, and the targeting of AID to Ig loci. 
Aicda transcripts are targeted by two miRNAs, miR-155 and miR-181, which 
regulate Aicda transcript levels (de Yebenes et al., 2008; Dorsett et al., 2008; Teng 
et al., 2008). The importance of miRNA-regulation is demonstrated by mouse 
models. Mice lacking a miR-155 target sequence in the AID 3’UTR exhibit 
substantially elevated AID expression that is inappropriately sustained after B 
cell exit from the germinal center (Dorsett et al., 2008; Teng et al., 2008). In 
addition to the predictably elevated CSR, the disruption of miR-155 regulation 
leads to hypermutation in non-Ig loci (Teng et al., 2008) and chromosomal 
translocations (Dorsett et al., 2008), pointing to the importance of miRNAs in 
preventing promiscuous AID activity.  
 Post-translational modifications of the AID protein also seem to be 
essential for physiological AID function. In particular, phosphorylation of the 
Ser38 residue by the cAMP-dependent protein kinase A (PKA) is required to 
recruit replication protein A (RPA), an important AID co-factor; disruption of 
this phosphorylation event decreases SHM and CSR by 70% (Cheng et al., 2009; 
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McBride et al., 2008). Furthermore, complexes of phosphorylated AID, PKA and 
RPA are localized to switch regions of the Igh locus. When PKA is catalytically 
inactivated, preventing AID phosphorylation, RPA is not recruited to the switch 
region and CSR is impaired, highlighting the importance of the post-translational 
modification and additional targeting factors on the localization of AID activity 
(Vuong et al., 2009).  
The precise mechanism which targets AID activity to the Ig loci is largely 
unresolved. As highlighted above, PKA and AID are targeted to switch regions, 
and the phosphorylation of AID by PKA leads to the recruitment of RPA and the 
initiation of CSR. This finding was further underscored in a genome-wide 
analysis of RPA occupancy, in which RPA was associated mainly with the Ig loci, 
an interaction that was dependent on AID phosphorylation (Yamane et al., 2011). 
Extensive work has pinpointed AID activity to regions of active transcription, 
where the transcriptional machinery has exposed a ssDNA substrate for AID 
(reviewed in Di Noia and Neuberger, 2007; Nussenzweig and Nussenzweig, 2010; 
Peled et al., 2008). In a current model, AID is targeted to a stalled RNA 
polymerase II (Pol II) by the co-factor Suppressor of Ty 5 homolog (Spt5), a 
stalling factor (Pavri et al., 2010). While this work exemplifies the importance of 
certain co-factors and post-translational modification in targeting AID to stalled 
Pol II and actively transcribed genes in the Ig loci, there are many unanswered 
questions. This is particularly complex, as AID needs to act specifically at the 
V(D)J region during SHM and the switch region during CSR. How this intricate 
targeting occurs is especially important in context of the genome-wide non-Ig 
activity of AID.  
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Despite many modes of tight regulation, it is clear that AID has significant 
activity beyond the Ig loci and can contribute to oncogenesis. AID-catalyzed 
mutations can be found throughout the genome, and in a variety of oncogenes 
and tumor-suppressor genes (Gordon et al., 2003; Pasqualucci et al., 2001; Pavri 
et al., 2010; Robbiani et al., 2009; Shen et al., 1998; Yamane et al., 2011). In total, an 
estimated 25% of the genes expressed in germinal center B cells are mutated by 
AID, albeit at levels considerably lower than in the Ig loci (Liu et al., 2008). 
Additionally, deep sequencing identification of the genomic locations of AID 
places it at the promoters of over 5000 genes in association with its co-factor Spt5 
and a stalled RNA Pol II (Pavri et al., 2010; Yamane et al., 2011). While AID 
targeting seems to be extensive, much of the genome seems to be protected from 
deleterious AID-mediated mutation and chromosomal translocation. Mice 
deficient in mismatch and base-excision repair enzymes exhibit strikingly higher 
mutation rates at non-Ig loci than wild-type littermates, suggesting that 
physiological error-free base-excision and mismatch repair resolves the majority 
of aberrant deaminase activity (Liu et al., 2008). AID-mediated tumorigenesis, 
therefore, occurs more frequently when in concert with an additional pro-
oncogenic factor, such as deficient DNA repair or heightened AID activity. 
Indeed, mice exhibiting uncontrolled AID expression have increased mutation 
rates and develop tumors as a result of AID mutations in oncogenes and tumor 
suppressors (Okazaki et al., 2003).  
In humans, AID is expressed in some B cell lymphomas (Lenz et al., 2007; 
Wright et al., 2003), and double-stranded breaks introduced in CSR are proposed 
to lead to oncogenic chromosomal translocations, especially the c-myc/IgH 
translocation associated with Burkitt’s Lymphoma (Pasqualucci et al., 2001; 2008; 
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Shaffer et al., 2002). In mice, AID can induce double-stranded breaks throughout 
the genome (Hasham et al., 2010) and was shown to be essential for c-myc/IgH 
translocations (Kovalchuk et al., 2007; Ramiro et al., 2006; 2004; Takizawa et al., 
2008) as well as other translocations not involving the Ig loci or c-myc (Lin et al., 
2009; Robbiani et al., 2009). Interestingly, the dysregulation of AID alone is not 
sufficient to cause such chromosomal instability or B cell malignancy (Muto et 
al., 2006; Okazaki et al., 2003); tumors observed in AID transgenic mice were 
predominantly of epithelial and T cell-origin and not associated with a 
chromosomal translocation (Okazaki et al., 2003). However, compound p53-
deficient/AID transgenic mice rapidly succumb to a set of phenotypically 
diverse B cell lymphomas, harboring Ig and non-Ig chromosomal translocations 
(Robbiani et al., 2009). Additionally, exogenous introduction of a DSB at known 
AID targets, Myc or IgH, leads to AID-dependent translocations at these loci 
(Robbiani et al., 2008). Genome-wide profiling of these genetically manipulated 
translocations reveals a wide spectrum of possible AID-mediated translocations 
with particular abundance in transcribed genes and at transcription start sites 
(Chiarle et al., 2011; Klein et al., 2011). Overall, AID-mediated mutations and 
chromosomal translocations can occur throughout the genome, but 
physiologically, these unwanted AID-mediated events occur at an extremely low 
frequency.  
AID activity outside of the Ig loci may not always be pathological. AID is 
expressed in primordial germ cells and embryonic stem cells (Morgan et al., 
2004) and reports have implicated AID in vertebrate DNA demethylation 
(Bhutani et al., 2010; Popp et al., 2010; Rai et al., 2008). However, this result is not 
corroborated in B cells where genome-wide methylation profiles are unaffected 
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by AID-deficiency or over-expression (Fritz et al., 2013). Furthermore, specific 
AID-dependent demethylase activity has not been firmly established and may be 
only occurring in lower vertebrates. While the proposed model is intriguing, 
further studies are needed to characterize any bona fide role for AID and/or other 
cytidine deaminases in developmental reprogramming.  
 
1.3.2. The APOBEC3 family of anti-retroviral enzymes 
 The APOBEC3 subfamily predominantly function in the restriction of 
retrovirus and endogenous retro-elements. As described above, the APOBEC3 
cytidine deaminases have undergone a massive gene expansion in the primate 
lineage, presumably in response to their rapidly evolving pathogen substrates. 
The subfamily members, APOBEC3A-H, act on a diverse set of retroviral 
substrates and vary in their abilities to suppress certain viruses. The best-
characterized example is APOBEC3G restriction of HIV infection. The function of 
APOBEC3G was discovered during the characterization of a specific HIV 
protein, virion infectivity factor (Vif) and the infectious profile of Vif-deficient 
(ΔVif) HIV. ΔVif HIV produced in primary human T cells or macrophages (and 
certain other cell-lines) exhibited a significantly diminished infectivity that was 
absent from a wild-type HIV (Gabuzda et al., 1992; Schwedler et al., 1993). These 
cells were termed “non-permissive cells” and were subsequently determined to 
express a specific anti-viral factor that was normally inhibited by Vif (Madani 
and Kabat, 1998; Simon et al., 1998). A subtractive cDNA screen comparing the 
transcript expression profiles of closely related “permissive” and “non-
permissive” cell-lines identified this restriction factor as the cytidine deaminase, 
APOBEC3G (Sheehy et al., 2002).  
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The potent viral restrictive activity of APOBEC3G in a ΔVif HIV infection 
occurs partially through its cytidine deaminase activity, specifically in its ability 
to massively hyper-edit viral cDNAs (Harris et al., 2003; Lecossier et al., 2003; 
Mangeat et al., 2003). During a ΔVif HIV infection of non-permissive cells, 
APOBEC3G is incorporated into the budding virus core through an interaction 
with viral RNA (Khan et al., 2005; Svarovskaia et al., 2004) and the viral Gag 
nucleocapsid protein (Schäfer et al., 2004). In newly infected cells, APOBEC3G 
remains associated with reverse transcription machinery and actively deaminates 
the nascent retroviral (-) strand cDNA (Harris et al., 2003; Mangeat et al., 2003; 
Yu et al., 2004b; Zhang et al., 2003). Most of these modified retrotranscripts are 
subsequently degraded. The rest of the edited cDNAs are integrated as 
devastatingly mutated and therefore defective proviruses (Kieffer et al., 2005). 
Additionally, APOBEC3G association with viral genomic RNA is thought to 
inhibit the tRNA priming of reverse-transcription, pointing to both deaminase-
mediated as well as editing-independent mechanisms for the APOBEC3G 
inhibition of ΔVif HIV virion production (Bishop et al., 2006; Guo et al., 2006; 
2007).  
During wild-type HIV infection, Vif protects the virus from APOBEC3G 
activity by targeting the deaminase for degradation and preventing its 
incorporation into packaging virions (Conticello et al., 2003; Marin et al., 2003; 
Mehle et al., 2004; Sheehy et al., 2003). To accomplish this, Vif binds APOBEC3G 
and recruits a specific ubiquitin ligase complex that poly-ubquitinates 
APOBEC3G and targets it for proteosomal degradation (Kobayashi et al., 2005; 
Yu et al., 2003). The Vif:APOBEC3G interaction is quite specific-specific; human 
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Vif is unable to inhibit a simian APOBEC3G and simian Vif has no effect on 
human APOBEC3G (Mariani et al., 2003). Overall, the fact that a retrovirus 
developed a distinct factor to combat a specific host anti-viral enzyme points to 
the incredible importance of the APOBEC3s in viral restriction.  
Aside from HIV, APOBEC3 family members have been shown to suppress 
the activity of a diverse set of viruses including simian immunodeficiency virus, 
equine infectious anemia virus, murine leukemia virus (MLV), foamy virus 
adeno-associated virus (AAV) and HBV (reviewed in Rosenberg and Papavasiliou, 
2007; Smith, 2011; Smith et al., 2012 and many others). Overall, the APOBEC3s 
act predominantly on retroviruses and as described for APOBEC3G, deaminate 
the single-stranded DNA substrate initially reverse transcribed from the viral 
RNA genome. While HBV is not a true retrovirus it requires reverse-transcription 
to replicate its double-stranded DNA, providing the appropriate substrate for 
APOBEC3s. AAV is a small single-stranded DNA parvovirus that is restricted by 
APOBEC3A (Chen et al., 2006), suggesting that certain APOBEC3s may exhibit 
more broad antiviral activity and act on non-retroviral pathogens.  
 The APOBEC3G gene has exhibited high rates of positive selection 
throughout primate evolution, but this selection seems to have mostly occurred 
before the emergence modern primate lentiviruses (Sawyer et al., 2004). As such, 
the ancestral function of the APOBEC3 family was proposed to also involve the 
restriction of endogenous retroelements, which include the long terminal repeat 
(LTR)-containing endogenous retroviruses (ERVs), and non-LTR sequences such 
as the long interspersed nuclear element-1 (LINE-1). Indeed, human ERVs carry 
footprints of ancient APOBEC3G deamination (Armitage et al., 2008), and the 
expansion of the APOBEC3 gene into the eight-member subfamily seems to have 
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coincided with a marked reduction in active retroelements in humans. In 
contrast, murine genomes from which only one copy of APOBEC3 is expressed, 
contain abundant retroelements some of which are still mobile in vivo (reviewed in 
Schumann, 2007).  
The mechanism by which APOBEC3 cytidine deaminases would restrict 
these endogenous retroviruses is predominantly thought to mimic APOBEC3G 
restriction of HIV, but other editing-independent mechanisms have also been 
proposed. Regardless of mechanism, the majority of the human APOBEC3s have 
been shown to inhibit retrotransposition of ERVs (Esnault et al., 2005) and LINE-
1 elements (Muckenfuss et al., 2006). The APOBEC3s have varied specificities 
and combat retroelements on two subcellular fronts, suggesting that the 
expansion of the APOBEC3 lineage into a diverse arsenal of immune enzymes 
may have been required to restrict the threat of endogeous retroelements.  
As has been described for AID, the APOBEC3s have the potential to 
promote oncogenesis through DNA editing activities. Specifically the nuclear-
localized deaminases APOBEC3A and B pose an increased threat to genomic 
integrity (Bogerd et al., 2006; Landry et al., 2011). As such, APOBEC3B was 
recently identified as a source of oncogenic mutation in breast cancer (Burns et 
al., 2013). Presumably for both APOBEC3 and AID, their key host defense 
functions outweigh the risk they pose for cellular transformation. 
1.3.3. APOBEC2 and APOBEC4: orphan deaminases  
 APOBEC2 was originally identified through an expressed sequence tags 
(EST) database search for the APOBEC1 ZDD and was proposed to be an RNA-
editing enzyme based on its close homology to APOBEC1 (Anant and Davidson, 
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2000; Liao et al., 1999). However, mutator assays have revealed no deaminase 
activity on cytidine, either as a free nucleotide or as a part of a DNA strand (Mikl 
et al., 2005; Nabel et al., 2012). Despite its apparent catalytic inactivity, there is 
some evidence for a further function for APOBEC2. APOBEC2 is exclusively 
expressed in cardiac and skeletal muscle (Liao et al., 1999; Mikl et al., 2005) and 
APOBEC2-deficient mice exhibit a distinct skeletal muscle phenotype. 
APOBEC2-deficiency leads to a fast-to-slow twitch muscle switch in the soleus 
muscle and eventual myopathy (Sato et al., 2010). Similarly, in zebrafish, 
morpholino knockdown of the two APOBEC2 proteins leads to a dystrophic 
phenotype and diminished heart function (Etard et al., 2010). These studies point 
to a conserved function for APOBEC2 in muscle development.  
Further work in zebrafish has implicated both AID and APOBEC2 in 
DNA demethylation (Rai et al., 2008). And, APOBEC2 has been shown to be 
essential for left-right axis determination in Xenopus and zebrafish (Vonica et al., 
2011). While it is clear that APOBEC2 acts in skeletal muscle function in mice and 
may have additional functions in lower vertebrates, the particular targets and 
mechanisms of these roles remain uncertain. Furthermore, it has never been 
established that APOBEC2 is catalytically active, suggesting that the observed 
phenotypes are due to an editing-independent function or that APOBEC2 editing 
requires the assistance of a co-factor or auxiliary protein complex missing from in 
vitro conditions.  
 APOBEC4 is a computationally predicted member of the AID/APOBEC 
family and contains the characteristic ZDD domain, suggesting that it is likely a 
cytidine deaminase of RNA or DNA (Rogozin et al., 2005). APOBEC4 expression 
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is primarily restricted to the testis but no editing targets or functions for this 
enzyme have been defined in that tissue.  
 
1.4. APOBEC1 
   
1.4.1. APOBEC1 editing of the Apob transcript 
 The first polynucleotide cytidine deaminase, APOBEC1 was identified as 
the catalyst of a well-characterized RNA-editing event in the transcript of 
Apolipoprotein B (Apob). ApoB exists in two distinct, tissue-specific protein 
isoforms, translated from a single mRNA transcript (reviewed in Kane, 1983). The 
full-length isoform, apoB-100, is synthesized in the liver and is an essential 
component of very low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL) and low-density (LDL) particles. ApoB-100 is required for the 
generation of hepatic VLDL particles and for transport of endogenously 
produced triglycerides in the blood. Additionally, it remains associated with the 
lipoprotein during the conversion of VLDL to IDL and then LDL particles, and 
serves as the ligand that mediates the clearance of LDL cholesterol by the LDL 
receptor pathway. The truncated isoform, apoB-48 is named as such because it is 
comprised of the N-terminal 48 amino acids of apoB-100. It is solely expressed in 
the intestine, where it is incorporated into chylomicrons and functions in the 
absorption and transport of dietary lipid (reviewed in Chan, 1992). The translation 
of apoB-48 is the result of a site-specific deamination of the cytidine to uridine at 
nucleotide 6666 (C6666) of the Apob transcript, the first identified mRNA editing 
event in mammals. The C-to-U modification creates a pre-mature stop codon 
(UAA) from a glutamate codon (CAA) and leads to the synthesis of the truncated 
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apoB-48 isoform from a full-length Apob transcript (Chen et al., 1987; Powell et 
al., 1987) (Figure 1.4).  
As the catalytic component of a multi-protein editing complex, APOBEC1 
mediates the site-specific deamination of C6666 (Teng et al., 1993). APOBEC1 is a 
zinc-dependent polynucleotide cytidine deaminase and the founding member of 
the AID/APOBEC polynucleotide cytidine deaminase family (Barnes and Smith, 
1993; Navaratnam et al., 1993; 1995). In humans, APOBEC1 expression is 
restricted to the small intestine, correlating with the intestine-specific generation 
of the apoB-48 protein isoform (Lau et al., 1994). Notably, APOBEC1 is not 
expressed in the human liver, resulting in the exclusive production of apoB-100. 
As such, APOBEC1 mediates the tissue-specific differential expression of apoB 
isoforms. In mice, APOBEC1 is expressed in a variety of tissues including both 
the liver and the small intestine (Hirano et al., 1997; Nakamuta et al., 1995), and 
apoB-48 is produced in both cell tissues (Greeve et al., 1993). Both Apob editing 
and formation of the apoB-48 isoform are completely dependent on APOBEC1; 
APOBEC1-deficient mice display no C-to-U editing at C6666 and produce only 
apoB-100-containing lipoproteins (Hirano et al., 1996; Morrison et al., 1996; 
Nakamuta et al., 1996), a phenotype rescued by transgenic expression of 
APOBEC1 in the intestine (Blanc et al., 2012).  
 
1.4.2. Mechanism of APOBEC1 editing  
 Like the other members of the AID/APOBEC family, APOBEC1 is a zinc-
dependent cytidine deaminase and shares the common homologous cytidine 
deaminase domain (MacGinnitie et al., 1995; Navaratnam et al., 1995). However, 
it also has a distinct RNA-binding domain and is the only member of the 
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Figure 1.4. APOBEC1 editing of Apob transcript. APOBEC1 mediates the 
tissue-specific distribution of apoB isoforms. In the liver, Apob is translated into 
its full-length isoform, apoB-100, which contains two domains: lipoprotein 
assembly domain and LDL receptor binding domain. ApoB-100 is an essential 
component of hepatic LDL particles. In the small intestine, APOBEC1                
deaminates cytidine 6666 in the Apob transcript, converting a glutamine codon 
(CAA) into a stop codon (UAA). This leads to the translation of a truncated 
isoform of apoB, designated apoB-48, which is incorporated into chylomicrons 
along with dietary lipid absorbed from the small intestine. 
LIPOPROTEIN ASSEMBLY
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deaminase family with a known RNA substrate (Anant et al., 1995; MacGinnitie 
et al., 1995; Navaratnam et al., 1995). The mechanism and localization of 
APOBEC1-mediated editing of the Apob mRNA transcript is well characterized. 
Apob editing is an intra-nuclear event; APOBEC1 shuttles from the cytoplasm to 
the nucleus (Chester et al., 2003; Yang et al., 1997) and edits Apob in a nuclear 
process coinciding with, or immediately following, splicing and polyadenylation 
(Lau et al., 1991). APOBEC1 functions as a homodimer to edit the Apob mRNA 
transcript (Lau et al., 1994; Oka et al., 1997); molecular modeling based on the E. 
coli cytidine deaminase ECCDA, suggests that one active site binds a 
downstream U, positioning the second functionally active deaminase at C6666 
(Navaratnam et al., 1998). 
 The predominant APOBEC1 editing event in the Apob transcript occurs at 
C6666. At 14kb, Apob is exceptionally large mRNA transcript and the precise 
targeting of the APOBEC1 “editosome” to this particular site is specified by the 
surrounding sequence elements. In general, APOBEC1 preferentially binds AU-
rich regions (Anant et al., 1995; Navaratnam et al., 1995) and is thought to target 
the conserved AU-rich sequences up and downstream of C6666. Specifically, a 
downstream 11nt “mooring sequence” (Shah et al., 1991) separated from the 
edited cytidine by a 4-6nt spacer element is absolutely required for Apob editing 
in vitro (Backus and Smith, 1992; Chen et al., 1990); even small deviations in the 
sequence or position of this “mooring” motif dramatically reduces or eliminates 
editing at C6666. In the context of the APOBEC1 editosome, introduction of a 
downstream mooring sequence is also sufficient to induce editing in a 
heterologous mRNA (Driscoll et al., 1993). Additional sequence features of Apob-
editing include 5’ and 3’ enhancer sequences which increase the efficiency of 
37
	   	  
editing (Backus and Smith, 1991; Driscoll et al., 1993; Hersberger and Innerarity, 
1998; Nakamuta et al., 1999). The importance of these sequence features was 
partially explained by secondary structure analysis of the Apob transcript. The 
mooring sequence and 5’ enhancer element comprise a conserved but imperfect 
stem, with the spacer element and edited cytosine forming an octa-loop. This 
stem-loop structure is essential for APOBEC1 editing; the loop positions C6666 at 
the APOBEC1 active site and the stem provides binding regions for the 
APOBEC1 editosome (Maris et al., 2005; Richardson et al., 1998). However, 
mutations to the mooring sequence which preserved the stem-loop also 
diminished editing efficiencies, pointing to both structural and sequence 
requirements for Apob editing (Richardson et al., 1998).  
 APOBEC1 edits Apob as a member of an incompletely characterized multi-
protein complex, the obligate components of which are APOBEC1 and its 
cofactor, APOBEC1 complementation factor (ACF) (Lellek et al., 2000; Mehta et 
al., 2000). ACF is a 64 kDa widely-expressed protein originally isolated from a 
baboon kidney extract found to “complement” APOBEC1 editing (Mehta et al., 
1996). The ACF protein exists in 4 major isoforms generated by alternative 
splicing events; each isoform has slightly differing abilities to mediate Apob 
editing (Dance et al., 2002; Sowden et al., 2004). The ACF protein contains three 
N-terminal RNA recognition motifs (RRMs), a C-terminal double-stranded RNA 
binding domain (RBD), and a nuclear localization sequence (Lellek et al., 2000; 
Mehta et al., 2000). During Apob editing, ACF binds the Apob transcript through 
its RRMs and forms a functional homodimer with an Apob mRNA bridge 
(Galloway et al., 2010). 
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 As a pair, recombinant ACF and APOBEC1 are necessary and sufficient to 
induce Apob editing in vitro (Lellek et al., 2000; Mehta et al., 2000). The 
established mechanism of APOBEC1 editing of C6666 in Apob is entirely 
dependent on ACF at multiple points. First, ACF binding of the mooring 
sequence targets APOBEC1 to C6666 and mediates the relative fidelity of this 
editing event (Mehta et al., 2000). As ACF binds to the mooring sequence it melts 
the stem loop secondary structure and exposes the target cytosine to the 
APOBEC1 (Maris et al., 2005). The newly edited transcript is transported from 
the nucleus as a part of the APOBEC1:ACF editosome, a complex that also 
protects the transcript from nonsense-mediated decay. Association with 
APOBEC1 alone is not sufficient to suppress degradation and also requires ACF 
binding to the Apob transcript (Chester et al., 2003). Finally, as the atypical NLS 
sequence in APOBEC1 is not sufficient to target a heterologous protein to the 
nucleus (Chester et al., 2003; Yang et al., 1997), there is some evidence that ACF 
may help drive the nuclear localization of APOBEC1, due to its strong NLS 
sequence (Blanc et al., 2001a; 2003). As such, ACF mediates many aspects of 
APOBEC1 editing in Apob save cytidine deamination: nuclear localization, 
position of the edited cytosine, substrate access and protection of the final edited 
product. Interestingly, the function of ACF seems to extend beyond this 
complementation of APOBEC1 editing; unlike APOBEC1, ACF-deficiency results 
in embryonic lethality in mice (Blanc et al., 2005). 
 Other than ACF, the distinct components of the APOBEC1 editosome 
remain poorly characterized. Some putative editosome factors have been 
identified based on their ability to bind APOBEC1, ACF or apoB (Harris et al., 
1993; Sowden et al., 2002). While they are not essential for editing, the majority 
39
	   	  
seem to function as regulatory factors. APOBEC1 binding proteins 1 and 2 
(ABBP1, ABBP2) have been shown to dramatically enhance editing at C6666 but, 
the majority of the identified editosome seem to function as negative regulators 
of C-to-U editing. Heterogeneous nuclear ribonucleoprotein C1 (hnRNP-C1), an 
mRNA splicing factor, was shown to be stringently bind to the Apob transcript 
around the edited C and function as an inhibitor of the APOBEC1 editing 
complex (Greeve et al., 1998). Two RNA-binding proteins with distinct homology 
to ACF also function to inhibit C-to-U editing events in Apob. CUG RNA-binding 
binding protein (CUGBP2) contains three RRMs and associates with APOBEC1 
in the cytoplasm and ACF and Apob in the nucleus. Anti-sense mediated 
knockdown of CUGBP2 dramatically increased the efficiency of Apob editing 
(Anant et al., 2001). Glycine-arginine-tyrosine rich RNA binding protein, (GRY-
RBP) can also bind to ACF, APOBEC1 and apoB and seems to inhibit C-to-U 
editing by sequestering ACF from the Apob transcript (Blanc et al., 2001b). 
However, immunodepletion of GRY-RBP abolished C-to-U editing in an 
APOBEC1-expressing human hepatoma cell-line, suggesting that this protein 
may function as both a positive and negative regulator of the APOBEC1 
editosome (Lau et al., 2001). The exact composition and action of the editosome 
remains unclear but the literature supports a model in which the assembled 
editosome works in concert to regulate APOBEC1 editing through inhibitory and 
stimulatory mechanisms.  
 
1.4.3. Additional APOBEC1 editing in the Apob transcript  
 Despite multiple modes of regulation, APOBEC1 editing of Apob is not 
entirely restricted to C6666. Sequencing of human Apob transcripts revealed a 
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secondary low-frequency APOBEC1 editing event at C6802. This editing event 
has the potential to cause a Thr to Ile substitution but, as it occurs concurrently 
with the upstream C6666 editing event that introduces a stop codon, has no 
consequence for the final protein composition (Navaratnam et al., 1991). 
Recently, a number of low frequency (~10%) promiscuous hyper-editing events 
were observed downstream of C6666 in mouse Apob transcripts (Blanc et al., 
2012). None of these editing events introduced a stop codon and the functional 
relevance of these additional edited sites is unclear. Likely, either through 
processive editing or low-affinity binding to AU-rich sequences, APOBEC1’s 
standard behavior includes some low-frequency “background” editing with little 
biological consequence.  
 More abundant hyper-editing of Apob was observed in vitro and in vivo 
during over-expression of APOBEC1 (Sowden et al., 1996a; Yamanaka et al., 
1996). This hyper-editing activity is proposed to be due to the altered 
stoichiometry between APOBEC1 and the editosome complex. In this model, 
abundant levels of APOBEC1 overwhelm the endogenous repertoire of the 
regulatory editosome and aberrantly edit as an independent enzyme in AU-rich 
regions.  
However, APOBEC1 has only been shown be capable of editing activity 
without ACF in elevated temperature environments, where the stem-loop 
structure of the Apob transcript is naturally disrupted (Chester et al., 2004; Maris 
et al., 2005). Furthermore, there is a dispute in the literature as to whether this 
hyper-editing is associated with mooring sequences, calling into question 
whether ACF mediates hyper-editing events (Hersberger and Innerarity, 1998; 
Yamanaka et al., 1996). Further investigation is needed to determine the 
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mechanism of APOBEC1-mediated hyper-editing and to elucidate the 
importance of ACF complementation of APOBEC1 editing in targets beyond the 
canonical C6666 event.  
 
1.4.4 Editing-independent roles for APOBEC1  
Independent of its catalytic activity, APOBEC1 has been demonstrated to 
bind AU-rich 3’UTRs, altering the transcript stability and modulating protein 
expression. APOBEC1 regulates the transcript 3’UTRs of Cox-2 (Anant et al., 
2004), Myc (Anant et al., 2000) and Cyp7a1 (Xie et al., 2009) in this manner with 
varying biological consequences. APOBEC1 stabilization of Cox-2 transcript 
serves a protective role after radiation injury (Anant et al., 2004) and may 
contribute to tumor formation in Apcmin/+ mice (Blanc et al., 2007). Aberrant 
regulation of Cyp7a1 in Apobec1-/- mice is proposed to lead to the gallstone 
susceptibility phenotype observed in these animals. However, the majority of 
work on APOBEC1 binding activity has come out from one specific group; 
alternative views in the field suggest that APOBEC1 has relatively poor RNA-
binding capabilities (Smith et al., 2012). Overall, these editing-independent 
functions of APOBEC1 suggest a broader role for this enzyme than had been 
previously appreciated but this work remains to be firmly established.  
 
1.4.5 Oncogenic APOBEC1 mRNA targets  
Transgenic over-expression mouse models have revealed potentially 
oncogenic APOBEC1 editing events that do not represent physiological targets. 
Mice with transgenic hepatic over-expression of APOBEC1 developed 
hepatocellular carcinomas, associated with the hyper-editing of the novel 
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APOBEC1 target-1 (Nat1) mRNA transcript (Yamanaka et al., 1997). An 
additional target, the mouse protein tyrosine kinase Tec, was also edited in a 
mooring sequence-dependent fashion. However, this editing resulted in a silent 
codon change that did not contribute to APOBEC1-mediated oncogenesis 
(Yamanaka et al., 1995). Nat1 editing occurs upstream of an imperfect mooring 
sequence, suggesting that the mechanism of this edited event was comparable to 
that established for Apob, albeit in a non-physiological system.  
Analysis of peripheral nerve-sheath tumors from patients with 
Neurofibromatosis type I (NF1) has revealed a C-to-U RNA-editing event 
attributable to APOBEC1 in the transcript of the tumor suppressor (also called 
NF1) whose loss-of-function is associated with development of the disease. This 
editing event introduces a premature stop codon, leading to the synthesis of an 
inactive protein. APOBEC1 is expressed in these NF1 tumors and the editing 
event occurs upstream of a mooring sequence, indicating that it is likely a true 
APOBEC1-catalyzed event (Mukhopadhyay et al., 2002; Skuse et al., 1996). 
However, editing was only apparent in a subset of patient samples and at a low 
editing frequency, suggesting that while this editing may contribute to NF1 
pathogenesis in some cases, it is not a physiologically significant APOBEC1 
target.  
A link between APOBEC1 and oncogenesis was further supported by 
studies implicating APOBEC1 in susceptibility to testicular germ cell tumors 
(TGCTs) (Nelson et al., 2012) and adenocarcinoma of the small intestine (Blanc et 
al., 2007) in tumor-susceptible mouse models. Most interestingly, APOBEC1-
deficiency reduced the small intestine tumor burden in compound Apcmin/+ 
;Apobec1-/- mice. Adenomas isolated from these mice had a marked reduction in 
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Cox-2 mRNA abundance that was not associated with any C-to-U editing (Blanc 
et al., 2007). While this points to an APOBEC1-mediated editing-independent 
mechanism of oncogenesis, there was no comprehensive search for APOBEC1-
mediated editing in these tumors. Transcriptome-wide sequencing of Apcmin/+ 
mice may reveal additional novel oncogenic APOBEC1 targets. 
 
1.4.6 Viral APOBEC1 targets  
There is some evidence supporting a role for APOBEC1 hyper-editing in 
the inhibition of viral transcripts. However, although viral restriction by other 
adenosine and cytidine deaminases (ADARs, APOBEC3s) is an abundant and 
widely investigated phenomenon, APOBEC1 editing of viral RNA and DNA is 
still poorly characterized. Mouse APOBEC1 has been shown to be capable of 
hyper-editing viral genomes and RNA during MLV infection. This hyper-editing 
activity was observed for in vitro and in vivo infections but occurred at an 
exceptionally low frequency and was not linked to viral restriction (Petit et al., 
2009). Similarly, in vitro infection assays suggested that both human and mouse 
APOBEC1 could hyper-edit HBV DNA, but patient samples revealed only 
negligible editing in a pattern attributable to APOBEC1 (Gonzalez et al., 2009). 
Although these studies suggest some viral editing by APOBEC1, the 
experimental techniques involved raise questions about the strength of the 
conclusions. First, the editing is detected using PCR techniques that selectively 
amplify edited products that naturally occur at an exceptionally low frequency. 
Also, the enzyme responsible for in vivo C-to-U editing in this work is 
determined by the enzyme preference for nucleotide 5’ to the edited cytosine, 
suggested to be TpC for APOBEC1. In Apob, C6666 is preceded by an A and 
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3’UTR targets of APOBEC1 are predominantly preceded by either an A or T(U), 
calling into question the validity of any exclusive preference for a 5’ T. However, 
more convincing studies have implicated APOBEC1 hyper-editing in the 
restriction of HSV-1 (Gee et al., 2011) and HIV (Ikeda et al., 2008) viruses. 
Overall, it is clear that APOBEC1 can edit viral ssDNA and RNA in vitro and 
some work points to a broader anti-viral function for APOBEC1 in certain viral 
infections. 
 
1.5. Transcriptome-wide discovery of RNA editing events  
 The field of RNA editing has been dramatically changed with the advent 
of high-throughput sequencing technology and the ability to search 
transcriptome-wide for novel RNA editing events. Much of the early work on 
RNA editing started with the identification of an important RNA modification, 
followed by the subsequent characterization of the enzyme responsible. With 
transcriptome-wide sequencing data, the number of known RNA editing events 
has dramatically expanded, but the characterization of the functional relevance 
of the majority of these novel sites has lagged behind. This is especially true for 
ADAR-catalyzed RNA editing events in mRNAs and miRNAs, which have been 
extensively profiled in humans, mice, C. elegans and Drosophila. Our lab has 
previously demonstrated the utility of a screen for cytidine deaminase-specific 
RNA editing in mice, which compares wild-type sequence to a deaminase-
deficient control to filter single-nucleotide variants (SNVs) for bona fide RNA 
editing (Rosenberg et al., 2011b). Here, I will focus on the many strategies 
employed in transcriptome-wide identification of A-to-I editing and C-to-U 
editing and the advantages and limitations of these techniques. 
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1.5.1 Transcriptome-wide strategies for identifying A-to-I editing 
 Initial transcriptome-wide discovery of RNA editing events involved 
mining publically available cDNA, EST, and DNA sequences for A-to-G 
mutations (Athanasiadis et al., 2004; Kim et al., 2004; Levanon et al., 2004). 
Another comparable study generated and sequenced a cDNA library, with 
similar results (Blow, 2004). As these publically available sequences have high 
error rates, the authors limited the search to likely ADAR targets, i.e. apparent 
ADAR clustering events or areas containing predicted RNA duplexes. These 
studies identified thousands of previously uncharacterized A-to-G(I) editing 
events, predominantly occurring in untranslated Alu repeats. This early work is 
additionally important as it set the stage for later high-throughput sequencing 
analyses and used many of the same bioinformatic techniques and strategies for 
sequence alignment and subsequent filtering of putative RNA editing events.  
 Next-generation sequencing technology allows for the massively parallel 
sequencing of whole genomes and transcriptomes. The majority of work 
searching for novel RNA editing has utilized transcriptome-wide sequencing 
(RNA-Seq). In classic mRNA-Seq, whole RNA isolated from a cell, tissue or 
organism of interest is subjected to a poly(A) selection, isolating polyadenylated 
mRNA transcripts, which are then fragmented, reverse transcribed and 
massively sequenced, yielding millions of reads that can be aligned to the 
reference genome or assembled de novo. Another permutation of RNA-Seq 
involving ribosomal RNA depletion in place of a poly(A)-selection, yields larger 
sequencing libraries as it includes non-poly(A) transcripts, such as many long 
non-coding RNAs (lncRNAs). Typically, to identify RNA editing events, single-
nucleotide variants (SNVs) between the RNA-Seq reads and the reference 
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genome are identified and massively filtered to remove false positives 
introduced by errors in DNA amplification, library sequencing, and read 
mapping. Additionally, many strategies involve the removal of single-nucleotide 
polymorphisms (SNPs) encoded in the genome.  
 The first example of the identification of RNA editing by high-throughput 
sequencing used a “target-capture” technique followed by massively parallel 
DNA sequencing of cDNA and gDNA derived from a single human individual 
(Li et al., 2009b). A set of ~35,000 padlock probes were designed based on 
previously identified RNA editing sites, excluding repetitive Alu elements. These 
padlocks probes are single-stranded primers containing two regions of 
complementarity designed to flank a specific region of interest in the target DNA 
strand. Once the complementary regions are hybridized to the target molecules, 
the gap between them is filled in by a polymerase and the subsequent pool of 
thousands of padlocks can be amplified and massively sequenced with an 
Illumina sequencer. This represented a landmark for the field of RNA editing as 
it demonstrated the utility of deep sequencing in the transcriptome-wide 
identification of RNA editing and identified over 200 novel RNA editing events. 
However, this technique has considerable limitations. First, it required the 
laborious generation of thousands of padlock probes. As the cost of oligo 
synthesis has subsequently fallen more slowly than that of high-throughput 
sequencing, it is now significantly less efficient than traditional RNA-Seq. 
Second, the padlock probe strategy was inherently biased as it relies on patterns 
established from previously identified editing events.  
 A subsequent technique was developed based on inosine cyanoethylation, 
termed inosine chemical erasing (ICE) (Sakurai et al., 2010). Cyanoethylated 
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inosines form N1-cyanoethylinosine (ce1I), which cannot base pair with C and 
therefore stalls reverse transcription machinery. In ICE, both cyanoethylated 
(Ce+) and un-cyanoethylated (Ce-) RNA samples from the same tissue were 
reverse transcribed, amplified and subjected to Sanger sequencing. The 
sequences of true RNA editing events would exhibit an A-to-G conversion in the 
Ce- sample that is absent from the Ce+ sample, due to inhibition of the reverse 
transcription machinery that occurred during cDNA conversion. False positives, 
such as A-to-G sequencing errors or SNPs, would be equally converted in both 
Ce- and Ce+ samples, and easily removed from the screen. The ICE technique 
was applied to hundreds of regions predicted to contain ADAR editing and led 
to the discovery of ~2500 novel editing events. ICE sequencing has been highly 
successful in identifying novel ADAR editing events and its strategy greater 
lowers false positive rates. However, like the padlock method, it is biased toward 
“likely” ADAR targets and can only identify A-to-I events, not the particular 
enzyme responsible.  
As the price of next generation sequencing has dropped, more groups 
were able to use RNA-Seq to search for RNA-editing events in an unbiased 
fashion across the transcriptome (Bahn et al., 2012). The major barrier for these 
techniques is differentiating bona fide RNA editing from SNPs or additional 
errors introduced during sequencing and mapping. A highly controversial study 
that identified widespread RNA and DNA differences (RDDs) across the 
transcriptome highlighted the challenge of this process and lead to follow-up 
work that defined more optimal practice for the identification of RNA editing. In 
their much discussed paper, Cheung and colleagues presented a transcriptome-
wide comparison of RNA and DNA sequences from human B cells, in which 
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they reported over 10,000 RDDs across the transcriptome, introducing 
tremendous informational complexity (Li et al., 2011). The most surprising part 
about this study was that many of these events were transversions incapable of 
being catalyzed by adenosine or cytidine deaminases, the only known enzymes 
to introduce RDDs. However, technical comments demonstrated that the 
majority of these events (>90%) were due to technical artifacts and genetic 
variation (Lin et al., 2012; Pickrell et al., 2012; Schrider et al., 2011). First, the 
Cheung group aligned reads to an incomplete transcriptome; although reads 
were aligned uniquely (i.e., discarding reads which aligned to more than one 
position), reads originating from gene paralogs missing from the incomplete 
reference aligned incorrectly, introducing apparent RDDs. Second, many of the 
identified RDDs displayed positional and strand biases, indicating that they were 
technical artifacts. A common place for these biases to be introduced was during 
first-strand cDNA synthesis, where 5’ mismatches can be introduced with the 
random hexamer, resulting in a 5’ end bias restricted to the negative strand (Lin 
et al., 2012). Finally, a substantial number were identified as genomic SNPs.  
The limitations of this report indicate that transcriptome-wide 
identification of RNA editing events must be employed with stringent alignment 
and filtering parameters. Reads must be uniquely and stringently mapped to the 
genome. Additional pre-alignment read trimming can remove end bias, but these 
can also be filtered later. After read alignment, a series of filters can reduce a 
false positives by eliminating strand-bias, low coverage sites, sites edited at 
100%, positional bias, repetitive regions, and known SNPs. A number of 
subsequent studies applying these more stringent alignment and filtering 
parameters to varying degrees have established a higher-confidence and ever-
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expanding inosome in introns, mRNAs, and miRNAs (Alon et al., 2011; Bahn et 
al., 2012; Danecek et al., 2012; Gu et al., 2012; Peng et al., 2012; Ramaswami et al., 
2012).  
 
1.5.2. Transcriptome-wide identification of APOBEC1 editing  
As discussed above, a major challenge in the identification of RNA-editing 
events is how to filter bona fide RNA editing events from genomically encoded 
SNPs. In 2009, I contributed to a manuscript from our lab describing a 
“comparative” RNA-Seq screen, which uses a deaminase-deficient control to 
partially overcome this barrier and identify bona fide deaminase-specific RNA 
editing events (Rosenberg et al., 2011b). However, this strategy is less effective in 
the identification of ADAR-specific events as Adar-/- mice are not viable. Some 
studies have been successful in siRNA-mediated knock-down strategies to 
identify ADAR editing events in certain cells lines, but this can be limited by the 
stringency of the knock-down (Bahn et al.). Applying the comparative RNA-Seq 
strategy to the transcriptome of small-intestinal enterocytes, we identified 32 
additional APOBEC1 editing targets, dramatically expanding the physiological 
editing repertoire of an editing enzyme previously reported edit one target.  
The comparative RNA-Seq strategy exploits the complete lack of 
APOBEC1-catalyzed Apob editing observed in Apobec1-/- mice. The transcriptomes 
of small intestine enterocytes derived from wild-type and APOBEC1-deficient 
mice were subjected to next-generation sequencing, yielding millions of 36nt 
reads. These reads were stringently aligned to the genome; after a series of 
quality filters, loci which contained a C-to-T mismatch in the wild-type sample 
that was absent from the APOBEC1-deficient sample were defined as APOBEC1-
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catalyzed RNA editing events. In this point, our technique exhibits a 
considerable advantage over many previously described A-to-I identification 
strategies in mice. The deaminase-deficient control greatly reduces the number of 
false positives introduced by genetic variation and sequencing errors and defines 
only deaminase-specific events. Furthermore, our screen was performed with 
highly stringent read quality, alignment and filtering parameters. Subsequently, 
further validation of the APOBEC1 editing events yielded a low false positive 
rate of ~15%.  
These newly identified APOBEC1 editing events were validated by 
standard Sanger sequencing of cDNA and gDNA from an additional pair of 
wild-type and Apobec1-/-mice. 33 of the 39 candidate sites were validated as bona 
fide APOBEC1 editing events. The edited frequencies of these sites were 
calculated from the RNA-Seq reads and ranged from 0.92 (in Apob) to 0.18. 
Additionally, analysis of Sanger sequences revealed some additional low-
frequency hyper-editing events surrounding certain identified editing sites. 
These resemble the low-frequency promiscuous editing observed in Apob (Blanc 
et al., 2012) and are of unknown relevance.  
Further analysis of these validated editing events revealed characteristic 
sequence features of APOBEC1 editing in Apob. Most prominently, a 
downstream mooring motif comparable to the 11-nucleotide mooring sequence 
was observed in most of the editing targets. This mooring motif, defined as 
WRAUYANUAU, is more flexible than the previously established mooring 
sequence (UGAUCAGUAU) essential for Apob editing and predominantly occurs 
4-6nt downstream of the targeted cytidine. A transcriptome-wide search for this 
mooring motif revealed that it is present in numerous transcripts, both in coding 
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and untranslated regions. We sequenced these transcripts with standard Sanger 
sequencing to look for APOBEC1 editing upstream of the putative mooring 
sequences. Although we identified 9 additional APOBEC1 3’UTR targets that 
had been missed by the original RNA-Seq screen, no editing was observed in 
coding regions. These results underscore the importance of the mooring 
sequence in directing APOBEC1 editing activity while also suggesting that 
APOBEC1 editing in coding regions may be a rare event regulated by auxiliary 
factors.  
Earlier analyses of APOBEC1 editing were essentially restricted to one 
target, so very little has been defined about the targeting and editing preferences 
of this enzyme. It has been demonstrated previously that APOBEC1 binds highly 
AU-rich regions and that the region flanking C6666 is AU-rich. To establish 
whether this was true for 3’UTR editing, we determined the nucleotide 
composition of the 100nt regions surrounding the validated APOBEC1 editing in 
3’UTRs. As a set, these were found to be substantially more AU-rich than 
random sets of 101nt. Additionally, the 101nt region within each 3’UTR that was 
edited by APOBEC1 was significantly more enriched in AU content than the 
surrounding sequence. Together, this suggests that, as in Apob, APOBEC1 binds 
AU-rich regions to promote efficient editing. The members of the AID/APOBEC 
family exhibit local preferences for the nucleotides flanking the targeted cytidine. 
To define similar preferences for APOBEC1, we assessed the nucleotide 
composition of the 4 nucleotides up and downstream of the edited cytidines. We 
found that there was a significant preference for A or U nucleotides at the 
positions immediately flanking the edited C.  
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Finally, we assessed whether the regions with observed APOBEC1 editing 
in 3’UTRs was conserved over evolution. We determined the phastCon scores for 
the 101nt windows centered upon edited cytidines and compared it to random 
101nt windows in the same 3’UTRs. Together, the APOBEC1 targeted regions in 
3’UTRs were significantly more conserved, suggesting that these regions may be 
of functional relevance.  
 Overall, this work established a highly-specific RNA-Seq screen for RNA 
editing and identified 32 novel APOBEC1 editing events in evolutionarily 
conserved regions of transcript 3’UTRs. While the functional importance of this 
untranslated RNA editing remains elusive, these results point to additional 
functions for APOBEC1 beyond its well-characterized role in lipid metabolism.  
 
1.6. Statement of problem  
Polynucleotide RNA and DNA editing function in a diverse set of 
biological processes in mammals. In particular, the activities of some well-
characterized cytidine and adenosine deaminases centers upon host defense, 
where editing events contribute to antibody diversification, restriction of 
retroviruses and endogenous retroelements, and suppression of the interferon 
response. Although much of this editing activity has also been linked to 
oncogensis, the essential immune functions imparted by this editing presumably 
outweigh the risk for cellular transformation. RNA editing is often additionally 
touted as a driver of transcriptome diversity, where post-transcriptional 
modifications increase the complexity of the genome (Bass, 2002). ADAR, the 
best characterized polynucletoide RNA editing enzyme, does seem to introduce 
some sequence diversity in targeted transcripts, especially in neurological tissue. 
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The majority of ADAR editing events, however, occurs within untranslated 
regions of targeted transcripts and may function to modulate gene expression 
rather than protein isoforms per se.  
Our lab has developed a comparative RNA-Seq screen to identify 
APOBEC1-specific RNA editing events transcriptome-wide. Application of this 
screen in small intestine enterocytes identified 31 novel APOBEC1-catalyzed 
editing events within transcript 3’UTRs. These newly identified targets were 
predominantly located in areas of high phylogenic conservation, implying 
functional relevance. Additionally, a subset overlapped with miRNA seed target 
regions, suggesting a role for APOBEC1 editing in modulating miRNA targeting. 
Overall, our work increased the known editing repertoire for APOBEC1 and 
points a broader function for APOBEC1 than previously established.  
Despite its expression in a variety of tissues (Hirano et al., 1996; 
Nakamuta et al., 1995), including secondary lymphoid organs and a number of 
immune cell types (Rosenberg and Papavasiliou, unpublished data), the study of 
APOBEC1 has remained focused on its roles in the digestive system. However, 
there is some evidence that APOBEC1 could also function in immune cells. 
Throughout primate evolution, members of the AID/APOBEC family have 
evolved rapidly, displaying some of the strongest signals of positive selection in 
the human genome (Sawyer et al., 2004), a pattern associated with host defense. 
Indeed, the majority of this family has well-conserved functions in the immune 
system. Furthermore, a role for RNA editing in immune function has been 
established for ADARs, who exhibit well-characterized functions in the 
interferon response, viral infection and the suppression of exogenous dsRNAs.  
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Here, I have used an adapted comparative RNA-Seq strategy to identify 
over 100 novel APOBEC1 editing events in transcript 3′UTRs of bone marrow-
derived macrophages (BMDMs), a cell type that express APOBEC1 without ACF 
or ApoB. Unlike APOBEC1 editing identified in the intestine, BMDM editing is 
only weakly associated with a mooring motif. These editing events occur 
predominantly in conserved regions of 3′UTRs and can be grouped into two 
distinct editing patterns: site-specific editing and hyper-editing. I further 
analyzed the downstream consequences of the newly identified APOBEC1 
editing events and found editing events that repressed protein expression in an 
experimental system. Finally, I assessed the interaction between APOBEC1 
editing and miRNA targeting and found little evidence that APOBEC1 was 
affecting miRNA binding. My results demonstrate dramatic physiological ACF-
independent APOBEC1 editing outside of the intestine and point to a role for 
these editing events in miRNA-independent transcript regulation in BMDMs. 
 












	   	  
Chapter 2: APOBEC1 mRNA editing in bone marrow-derived macrophages 
 
The development of high-throughput sequencing technology has led to 
the rapid identification of thousands of previously unknown RNA editing 
events, the majority of which fall within the untranslated regions of target 
transcripts. Although the functional relevance of most of these newly discovered 
editing events remain elusive, they point to a broader function for RNA editing 
than has been previously appreciated. In particular for APOBEC1, an enzyme 
whose activity was thought to be restricted to a lone target and a single role in 
lipid metabolism, the recognition that APOBEC1 can edit additional transcripts 
in enterocytes raises the possibility that its physiological activity may also not be 
constrained to the intestine. The hypothesis that APOBEC1 may edit transcripts 
in additional cell types was tested using an adapted comparative RNA-Seq 
strategy in bone marrow-derived macrophages (BMDMs), a cell-type which 
expresses APOBEC1 but lacks ACF or ApoB. Abundant APOBEC1 editing was 
identified in BMDM transcript 3′UTRs, occurring in two editing patterns: site-
specific editing and hyper-editing. These editing events represent the first 
example of physiological APOBEC1 editing outside of the intestine and point to 








	   	  
2.1 Identification of APOBEC1 editing events in BMDMs 
  
2.1.1. APOBEC1 expression in BMDMs 
While APOBEC1 RNA editing activity has previously been identified only 
in the small intestine and liver, it is expressed in a diverse set of tissues, 
including a number of immune cell types (Rosenberg and Papavasiliou, 
unpublished data). Notably, microarray data has shown that APOBEC1 is 
expressed in macrophages and that in this cell type expression levels are 
regulated by LPS stimulation (Mabbott et al., 2010). As these results point to a 
function for APOBEC1 in macrophages, I reasoned that bone marrow-derived 
macrophages (BMDMs) were an ideal experimental system with which to 
explore APOBEC1 editing in the immune system. Bone-marrow precursors were 
incubated with macrophage-specific cytokines (M-CSF) to generate mature 
macrophage cells, confirmed by two typical macrophage-specific cell surface 
markers, F4/80 and CD11b. Notably, Apobec1-/- BMDMs have no maturation 
defects and final cultures are >97% mature macrophages in both wild-type and 
APOBEC1-deficent littermates (Figure 2.1).  
APOBEC1 expression was confirmed by RT-PCR of mRNA derived from 
wild-type BMDMs. Surprisingly, in contrast to small intestine enterocytes, 
BMDMs lack APOBEC1’s known cofactor, A1cf, and its canonical editing target, 
ApoB (Figure 2.2A). This finding was further supported by RNA-Seq performed 
on wild-type BMDMs; both A1cf and ApoB transcript expression (represented as 
FPKM; fragments per kilobase per million reads mapped) were calculated to be 
zero, while APOBEC1 was expressed with an FPKM of approximately 261 






























Figure 2.1.  Flow cytometry analysis of BMDM maturation. Bone marrow 
precursors were derived from wild-type and APOBEC1-deficient mice and 
matured into bone marrow-derived macrophags (BMDMs). The final
composition of the “mature” BMDM cultures was confirmed via flow cytometry 
analysis.  Live cells were gated based on forward and side-scatter and lack of 
7AAD staining. Mature macrophages were identified with two cell surface 
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Figure 2.2. APOBEC1 expression in BMDMs. (A) PCR amplification of Apobec1, 
A1cf and Apob cDNA from macrophage and enterocyte mRNA. (B) Transcript 
expression data for Apobec1, A1cf and Apob from polyA+ RNA-Seq as calculated 
by cuffdiff, representated as fragments per kiolobase per million reads mapped 
(FPKM). (C) APOBEC1 expression after LPS stimulation as assessed by qRTPCR.
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in BMDMs stimulated by LPS (100ng/mL). Apobec1 transcript levels drop to 20% 
of baseline after 2 hours of LPS stimulation, and subsequently recover at 24 
hours. Together these results further point to a role for APOBEC1 in BMDMs. 
 
2.1.2. RNA-Seq reveals abundant APOBEC1 editing in BMDMs.  
The Papavasiliou lab has previously established a comparative RNA-Seq 
strategy with high specificity for the identification of RNA-editing events, which 
utilizes an APOBEC1-deficient control to filter single-nucleotide variants (SNVs) 
for APOBEC1-dependent RNA editing events (Rosenberg et al., 2011b; 2011a). As 
described in section 1.5.2, this screen revealed 32 additional APOBEC1 editing 
events in enterocyte transcript 3′UTRs, pointing to further functions for 
APOBEC1. To investigate the extent of APOBEC1 deaminase activity in murine 
macrophages, we performed 75nt, single-end RNA-Seq on poly-A+ RNA from 
wild-type and Apobec1-/- BMDMs, yielding approximately 28 and 33 million 
reads, respectively. These reads were trimmed and then aligned to the reference 
genome (mm9). The alignment strategy was designed mindful of the fact that the 
edited population of reads in the wild-type could contain many mismatches to 
the reference genome, essential to the downstream editing analysis. With this in 
mind, moderately permissive alignment parameters were used that allowed for 
up to 6 mismatches within a 75nt read.  
To identify putative APOBEC1-catalyzed deamination events, C-to-T 
SNVs between the reads and the reference genome were identified. To do this a 
pileup file was generated using the SAMtools program (Li et al., 2009a). The 
strategy for identifying these APOBEC1-mediated mismatches differed slightly 
from previously established protocols. Previously, read to reference mismatches 
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were determined using the SNP-calling algorithm defined by the SAMtools 
program during the generation of a pile-up file. But, as RNA editing events can 
occur in different patterns from genomic SNPs, it was suboptimal to use this 
SNP-calling algorithm to assign a consensus base. Therefore, process was 
somewhat simplified and SNVs were identified purely by the ratio of nucleotides 
present at that position in aligned reads.  
These identified APOEC1-specific C-to-T SNVs were further filtered, 
identifying those that fell within known genes, were covered by at least 20 reads, 
had at least 20% apparent editing, were not located in regions that were non-
isogenic between the mice used, were not significantly strand biased, and were a 
minimum distance from non-C-to-T SNVs. Finally, we retained only those C-to-T 
mismatches that did not occur in the Apobec1-/- sample, isolating true APOBEC1-
dependent events (Figure 2.3). To increase both sensitivity and specificity, we 
lowered parameters for the APOBEC1-deficient sample, identifying a base as 
“edited” if it was covered by at least 10 reads and had an editing frequency of at 
least 5%. Based on this filtering strategy, 110 putative APOBEC1 editing events 
within 72 transcripts were established (Figure 2.4). A comparable analysis was 
performed in the Apobec1-/- sample as compared to wild-type to estimate an 
implied false positive rate (IFPR) of <1%.  
A subset of editing events were validated by standard Sanger sequencing 
or subclone sequencing of cDNA and genomic DNA (gDNA) derived from an 
independent littermate pair of wild-type and Apobec1-/- BMDMs (Figure 2.6 - 2.8). 
We confirmed 42 editing events of 48 screened, for a false positive rate of 12.5%. 
This false positive rate was moderately higher than the predicted IFPR. A 
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Figure 2.3. Workflow for comparative mRNA-Seq strategy. The strategy for 
comparative RNA-Seq  read alignment and SNV filtering is depicted here.  After 
filtering, C-to-T mismatches identified in the sample wildtype sample that are 
absent from the APOBEC1-deficient BMDMs are designated as bona fide 
APOBEC1 editing events. The converse, C-to-T mismatches in the APOBEC1-





A 3’UTR: Aoah chr13:21115520-21115670
B 3’UTR: Sh3bgrl chrX:106355600-106357600
Figure 2.4. Examples of APOBEC1 editing events identified by RNA-Seq. 
(A/B) RNA-Seq reads from wildtype and Apobec1-/- libraries covering the 3’UTRs 
of Aoah (A) and Sh3bgrl (B) as visualized by the Integrative Genome Viewer. 
Nucleotides which match the reference genomic sequence are represented in 
grey and nucleotide mismatches to the reference genome are represented by a 




	   	  
of the APOBEC1 editing repertoire within each transcript, the elimination of a 
genomic SNP filter and the moderately permissive read depth cutoffs. After 
validation, we compiled a list of 104 high-confidence APOBEC1 editing events 
within 68 transcript 3′UTRs (Figure 2.5;Table 2.1), representing the first example 
of physiological APOBEC1 editing outside of the intestine.  
 
2.1.3 Two patterns of APOBEC1 editing: site-specific and hyper-editing 
In contrast to physiological APOBEC1 RNA editing in enterocytes, we 
observed two distinct APOBEC1 editing patterns in BMDMs (Figure 2.5). In site-
specific editing, a single cytosine is edited consistently at high frequency, with 
negligible frequencies of editing events surrounding the targeted base. Site-
specific editing, comparable to previously established APOBEC1 editing in ApoB, 
was observed in 54 transcripts 3ʹ′UTRs (containing 60 identified editing events) 
(Figure 2.5-2.7). In hyper-edited transcripts the 3ʹ′UTR contained multiple (2-8) 
high frequency editing events (editing “hotspots”) and many scattered low-
frequency editing events surrounding each “hotspot” base. APOBEC1-
dependent hyper-editing was observed in 14 APOBEC1-targeted transcripts 
(containing 44 identified editing events) (Figures 2.4, 2.8, 2.9). Some 
“promiscuous” APOBEC1 hyper-editing activity has been previously observed 
in transgenic over-expressing mice or a viral infection model, but never in a 
physiological system. Therefore, in addition to identifying abundant APOBEC1 
editing in a novel cell type, this represents a previously uncharacterized 
physiological editing modality for APOBEC1. 
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Gene name Edited Site Ref base Read base Read depth Strand Edit Frequency Hyperedited
1110002B05Rik chr12:55747165 G R 127 - 0.43 no
2010106G01Rik chr2:126716570 G R 46 - 0.35 no
2210013O21Rik chrX:150163433 C Y 42 + 0.21 no
2610001J05Rik chr6:13819970 G R 65 - 0.25 no
4930579G24Rik chr3:79436318 C Y 22 + 0.23 no
6330578E17Rik chr1:37475131 G R 30 - 0.20 no
Acadl chr1:66877651 G R 20 - 0.20 no
ADAM10 chr9:70626825 C Y 62 + 0.21 no
Anxa5 chr3:36347952 G R 594 - 0.31 no
Aoah chr13:21115534 C Y 24 + 0.25 yes
Aoah chr13:21115538 C Y 23 + 0.30 yes
Aoah chr13:21115541 C Y 23 + 0.22 yes
Aoah chr13:21115616 C Y 24 + 0.21 yes
Aoah chr13:21115667 C Y 23 + 0.22 yes
App chr16:84954725 G R 50 - 0.20 yes
App chr16:84954758 G R 133 - 0.46 yes
App chr16:84955024 G R 304 - 0.24 yes
App chr16:84955039 G R 257 - 0.20 yes
App chr16:84955062 G R 241 - 0.21 yes
App chr16:84955086 G R 254 - 0.23 yes
App chr16:84955113 G R 311 - 0.32 yes
App chr16:84955194 G R 265 - 0.28 yes
Arih1 chr9:59239901 G R 22 - 0.23 no
Atp6ap2 chrX:12193513 C Y 157 + 0.27 yes
Atp6ap2 chrX:12193524 C Y 149 + 0.23 yes
Atp6ap2 chrX:12193607 C Y 126 + 0.40 yes
Atp6v1a chr16:44087436 G R 143 - 0.23 no
B2m chr2:121978476 C Y 2350 + 0.51 yes
B2m chr2:121978523 C Y 1863 + 0.28 yes
B2m chr2:121978638 C Y 1770 + 0.54 yes
BC013529 chr10:7487994 G R 20 - 0.25 no
Bcap31 chrX:70931693 G R 112 - 0.21 yes
Bcap31 chrX:70931742 G R 127 - 0.20 yes
Bcap31 chrX:70931744 G R 126 - 0.31 yes
Casp6 chr3:129616676 C Y 28 + 0.29 no
Ccni chr5:93611225 G R 51 - 0.27 no
Cd36 chr5:17288955 G R 47 - 0.77 no
Cybb chrX:9012852 G R 196 - 0.29 yes
Cybb chrX:9013719 G R 260 - 0.22 yes
Dpp8 chr9:64929147 C Y 36 + 0.25 no
Dpp8 chr9:64930384 C Y 29 + 0.29 no
Dynlt3 chrX:9232850 G R 23 - 0.35 yes
Table 2.1. APOBEC1 editing events in BMDMs 
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Gene name Edited Site Ref base Read base Read depth Strand Edit Frequency Hyperedited
Dynlt3 chrX:9233008 G R 31 - 0.26 yes
Eif4a2 chr16:23113791 C Y 20 + 0.20 no
Entpd5 chr12:85716971 G R 20 - 0.20 no
Epsti1 chr14:78402303 C Y 25 + 0.24 no
Fkbp1a chr2:151386579 C Y 34 + 0.21 yes
Fkbp1a chr2:151387062 C Y 22 + 0.32 yes
Fuca2 chr10:13235355 C Y 20 + 0.25 no
Gdbd1 chr11:86847804 G R 23 - 0.26 no
Hibadh chr6:52496349 G R 38 - 0.24 no
Hmgn3 chr9:83003686 G R 22 - 0.23 no
Impa1 chr3:10314195 G R 22 - 0.23 no
Itgb2 chr10:77028321 C Y 200 + 0.23 yes
Itgb2 chr10:77028356 C Y 144 + 0.38 yes
Lamp1 chr8:13174686 C Y 368 + 0.21 yes
Lamp1 chr8:13174689 C Y 363 + 0.29 yes
Lamp1 chr8:13174696 C Y 418 + 0.32 yes
Lamp1 chr8:13174720 C Y 383 + 0.29 yes
Lamp1 chr8:13174732 C Y 399 + 0.39 yes
Lamp2 chrX:35774512 G R 67 - 0.27 no
Lamp2 chrX:35774742 G R 81 - 0.30 no
Lypla1 chr1:4836242 C Y 37 + 0.30 no
Mbnl1 chr3:60432599 C Y 147 + 0.20 no
mcmbp chr7:135841366 G R 25 - 0.32 no
Mmd chr11:90139728 C Y 31 + 0.29 no
Mospd2 chrX:161374490 G R 23 - 0.43 no
Nptn chr9:58500000 C Y 150 + 0.36 yes
Nptn chr9:58500149 C Y 162 + 0.20 yes
Ola1 chr2:72931513 G R 27 - 0.22 no
Ola1 chr2:72931552 G R 22 - 0.23 no
Papss1 chr3:131306342 C Y 24 + 0.21 no
Papss1 chr3:131306346 C Y 23 + 0.22 no
Pla2g7 chr17:43749067 C Y 86 + 0.24 no
Prkacb chr3:146395143 G R 36 - 0.22 no
Ptma chr1:88427075 C Y 43 + 0.23 no
Rab18 chr18:6789843 C Y 25 + 0.28 no
Rac1 chr5:144266732 G R 207 - 0.29 no
Reep5 chr18:34506411 G R 44 - 0.21 no
Rpl15 chr14:19100950 G R 32 - 0.25 no
Rpl15 chr14:19101348 G R 21 - 0.29 no
Sdcbp chr4:6322479 C Y 45 + 0.56 yes
Sdcbp chr4:6322512 C Y 85 + 0.64 yes
Sep15 chr3:144259976 C Y 286 + 0.37 yes
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Sep15 chr3:144260406 C Y 244 + 0.21 yes
Serinc1 chr10:57235791 G R 62 - 0.81 no
Serinc3 chr2:163450893 G R 109 - 0.23 no
Sgk3 chr1:9889105 C Y 30 + 0.37 no
Sgk3 chr1:9889140 C Y 21 + 0.29 no
Sh3bgrl chrX:106355759 C Y 112 + 0.28 yes
Sh3bgrl chrX:106356391 C Y 101 + 0.28 yes
Sh3bgrl chrX:106357513 C Y 182 + 0.25 yes
Spcs2 chr7:106987604 G R 31 - 0.26 no
Spp1 chr5:104869859 C Y 3284 + 0.22 no
Srgn chr10:61957357 G R 47 - 0.21 no
St8sia4 chr1:97484976 G R 20 - 0.25 no
Syap1 chrX:159295116 G R 20 - 0.20 no
Sypl chr12:33661093 C Y 45 + 0.20 no
Tes chr6:17055467 C Y 40 + 0.30 no
Tmed7 chr18:46747592 G R 26 - 0.31 no
Tmem30a chr9:79617629 G R 28 - 0.61 no
Tmem55a chr4:14841457 C Y 20 + 0.35 no
Tspan3 chr9:55983987 G R 34 - 0.26 no
Zfp871 chr17:32906699 G R 20 - 0.21 no
Table 2.1. Continued. APOBEC1 editing events in BMDMs 
67
Editing events (ranked by editing frequency) 
APOBEC1 editing by transcript 3’UTR 
site-specific
1 editing event 
site-specific
2 editing events 
5
2 editing events 
5
hyper-edited
























Figure 2.5. APOBEC1 site-specific editing and hyper-editing. Editing 
frequency of single-site edited (blue) and hyper-edited (green) sites. Inset: 
APOBEC1-targeted transcripts represented by editing pattern and number of 
events per transcript. 
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Figure 2.6 Representative example of APOBEC1 site-specific editing. 
(A) Sanger sequencing and (B) subclone sequencing of the Cd36 tran-
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Figure 2.7. Additional examples of APOBEC1-mediated site-specific editing. 





Figure 2.8. Representative example of APOBEC1 hyper-editing. Subclone 
sequences from the cDNA of wildtype and Apobec1-/-App transcripts aligned to 
the reference genomic sequence. C-to-T mismatches to reference are highlighted 
in yellow and editing events identified by RNA-Seq screen are indicated by 
arrows.
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Figure 2.9. Additional examples of APOBEC1-mediated hyper-editing. 
Subclone sequencing of (A) Lamp1 and (B) B2m transcript 3’UTRs.
B
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2.2 Characteristics of APOBEC1 editing events in BMDMs 
High-frequency APOBEC1 editing events had been identified in a cell 
type that lacks the co-factor ACF, suggesting that APOBEC1 could be editing in a 
previously uncharacterized mechanism. Analysis of APOBEC1 intestinal editing 
events has revealed sequence characteristics for editing that include A or U 
flanking nucleotides (Rosenberg et al., 2011b) and a downstream mooring motif 
(Backus and Smith, 1991; Rosenberg et al., 2011b; Shah et al., 1991). In ApoB 
editing, ACF binds to the mooring sequence and directs APOBEC1 to C6666 with 
high fidelity. Intestinal 3′UTR editing events are largely associated with a similar 
mooring motif, suggesting that ACF binding to the target transcript may also be 
required. To gain insight into mechanistic difference for APOBEC1 editing 
without ACF, I performed analyses to determine whether macrophage-specific 
APOBEC1 editing events shared the features of 3′UTR editing in the intestine. 
 
2.2.1 Adjacent nucleotide analysis  
Other members of the AID/APOBEC family have been shown to have 
preferences for the nucleotides neighboring the targeted cytosine. In small 
intestine enterocytes, APOBEC1 was found to exhibit a strong preference for A or 
U nucleotides immediately flanking the edited C (Rosenberg et al., 2011b). 
Analysis of the flanking nucleotides in BMDM edited transcripts revealed that 
again the edited cytosine was flanked by A or U more often than would be 
expected by chance (Figure 2.10). This result suggests that factors leading to a 
flanking nucleotide preference remain consistent in ACF-independent APOBEC1 
editing in BMDMs.  
 
73
Figure 2.10. APOBEC1 adjacent nucleotide preferences. Sequence log 
depicting the frequency of nucleotides in positions flanking the APOBEC1-
targeted cytosine. The height of the nucleotide depicts the relative frequency of 
each base at the specified position. 
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2.2.2 Mooring sequence analysis 
A downstream 11-nucleotide APOBEC1 mooring sequence was 
established in the intestine to be essential for ApoB editing (Shah et al., 1991) and 
was found to be strongly associated with 3ʹ′UTR editing (Rosenberg et al., 2011b). 
The sequence of the mooring sequence and the further refined “mooring motif” 
are depicted in Figure 2.12A. To further investigate features of ACF-independent 
APOBEC1 editing, the relationship of macrophage-specific APOBEC1 editing 
events with this mooring sequence was investigated. In contrast to enterocyte 
editing, only 33 APOBEC1-targeted transcripts (43% of hyper-edited transcripts 
and 54% of site-specific edited transcripts) were associated with a high-quality 
mooring sequence, defined as ≤ 2 deviations from the established mooring motif 
(Figure 2.11).  
To determine the correlation between mooring sequence strength and 
editing frequency, a mooring motif scoring system was defined based on 
sequence quality and position of the mooring motif in relation to the targeted 
cytosine (Figure 2.12A). For all APOBEC1 editing events identified, mooring 
sequence score was only weakly correlated (Pearson’s correlation coefficient r = 
0.39) with editing frequency (Figure 2.12B). However, hyper-editing events could 
skew these results, as only one mooring sequence may be associated with many 
editing events in one transcript 3ʹ′UTR. A comparable analysis limited to site-
specific editing events yielded only a slightly higher correlation (r = 0.55) (Figure 
2.12B). In hyper-edited transcripts, a very poor correlation was found between 
number of high-frequency edits (≥ 20%) in each transcript and mooring sequence 
stringency of the best mooring motif (r = 0.17) (Figure 2.12C). These data 
75




1 deviation from mooring motif
2 deviations from mooring motif
No mooring motif
Percentage of target transcripts
Figure 2.11. Presence of mooring motif in APOBEC1-targeted transcripts. 
Quality of the mooring motif in hyper-edited and single-site edited transcripts. 
Mooring motifs are grouped by the number of mismatches (0, 1, 2, > 2) to the 
established motif and represented as a percentage of the total number of hyper-
edited or site-specific editing transcripts. In transcripts with more than one 
edited C and more than one mooring sequence, the best motif was chosen.
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Figure 2.12. APOBEC1 editing is weakly associated with mooring motifs. (A) 
Schematic of APOBEC1 mooring sequence essential for ApoB editing of C6666 
(grey) and consensus mooring motif established for APOBEC1 3’UTR editing in 
enterocytes (green). Edited cytidine is represented in red. The mooring sequence 
stringency score was based on the distance of the mooring sequence and the 
quality of the mooring motif. (B) APOBEC1 editing events (site-specific, blue; 
hyper-edited, green) plotted as a factor of the mooring sequence score and 
editing frequency. Best-fit lines were plotted for all editing events (red) and only 
site-specific events (blue) (r = Pearson’s correlation coefficient). (C) The mooring 
motif score for hyper-edited transcripts is plotted against the number of 
APOBEC1 editing events/transcript. The “best” mooring motif score was used 
for transcripts with multiple motifs.
Mooring motif score (best for each transcript) 
Mooring motif score  
Apob mooring sequence
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Figure 2.13. Mooring sequence scores in BMDMs vs enterocyte editing 
targets. Edited transcripts were split into those only edited in BMDMs 
(purple) and those with editing events identified by RNA-Seq in both 
small-intestine enterocytes and BMDMs (blue).  Each transcript is plotted 
for the score of its mooring sequence. A score of 0 denotes the absence of a 
high-quality mooring sequence.  A score of 10 indicates a mooring sequence 
with no deviations from the established motif that occurs 4-6nt downstream 
of the edited cytosine. 
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demonstrate that ACF-independent APOBEC1 editing in BMDMs is occasionally 
associated with, but not absolutely dependent on, a downstream mooring 
sequence. Furthermore, this suggests that the requirements for APOBEC1-
dependent RNA editing in BMDMs may be substantially different than 
previously established for ApoB and points to an alternative editing requirements 
for these ACF-independent editing events. 
 
2.2.3 Comparison of APOBEC1 intestine and BMDM editing  
The editing of C6666 in the ApoB transcript remains the only example of 
true APOBEC1 editing in a coding region, but some APOBEC1 transcript 3ʹ′UTR 
substrates displayed similar editing in both enterocytes and BMDMs. In 
isolation, this result is not surprising; cis-acting sequence requirements for 
APOBEC1 editing in preferred substrates could “mark” the transcript for editing. 
However, one of these sequence requirements is the binding motif for a co-factor 
not expressed in BMDMs. As discussed, while half of the transcripts edited in 
BMDMs lack a downstream mooring sequence, some transcripts are associated 
with high quality mooring motifs. However, when the transcripts are grouped 
into those edited only in BMDMs and those also edited in the intestine, 
transcripts edited in both cell types tend to have higher mooring sequence scores 
(Figure 2.13). This finding points to additional uncharacterized sequence 
requirements or an alternative co-factor involved in APOBEC1-mediated 





	   	  
Chapter 3: Consequences of APOBEC1 editing events in 3’UTRs  
 
 Transcriptome-wide high-throughput sequencing has revealed thousands 
of previously uncharacterized ADAR and APOBEC1 RNA editing events in 
transcript 3′UTRs. The functional relevance of this untranslated region editing 
has remained largely unknown. Specific examples of ADAR editing in 3’UTRs 
have been shown to modulate genes expression through nuclear retention of 
ADAR target transcripts (Chen et al., 2008), mRNA cleavage (Osenberg et al., 
2009) or potential modification of miRNA target regions (Borchert et al., 2009; 
Liang and Landweber, 2007). For APOBEC1, the identification of additional 
editing events in enterocyte transcript 3’UTRs pointed to a broader role for the 
enzyme than had been previously appreciated. These additional editing events 
intestine enterocytes were shown to occur predominantly in evolutionarily 
conserved regions, suggesting that untranslated APOBEC1 may have functional 
importance. Furthermore, the majority of APOBEC1 editing events were shown 
to occur in sequences matching miRNA seed targets, suggesting that APOBEC1 
editing could alter gene expression by influencing miRNA targeting. However, 
as functional testing of APOBEC1 editing in enterocytes was complicated by 
APOBEC1’s role in lipid metabolism, the specific consequences of APOBEC1 
editing in 3’UTRs remained elusive.  
 Chapter 2 described the identification of abundant APOBEC1 editing 
events in BMDMs, the first example of physiological APOBEC1 editing outside 
of the digestive system. BMDMs are a preferable experimental system to test 
functional relevance of APOBEC1 editing in transcript 3’UTRs as:  
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1- BMDMs are a robust primary cell type, providing both a physiological 
milieu and abundant, easily culturable material.  
2- APOBEC1-deficient BMDMs are unaffected by the lipid defects that 
afflict Apobec1-/- small intestine enterocytes due to the loss of apoB-48. 
These apoB-mediated effects complicate analysis of small-intestinal 
enterocyte editing where it is impossible to differentiate apoB-mediated 
defects from those caused by alternative APOBEC1 editing events.  
3- As discussed, there is significant evidence that APOBEC1 may function 
in the immune system. As BMDMs have abundant APOBEC1 enzymatic 
activity, this cell type represents an appropriate system to assess roles for 
APOBEC1 in immunity.  
 Therefore, BMDM APOBEC1 editing events in 3’UTRs were assessed for 
consequences for transcript expression, gene expression and cell function. As a 
set, APOBEC1 editing events were found in evolutionarily conserved regions. 
Although transcripts found to be edited by APOBEC1 had no significant 
differences in overall protein expression between wild-type and APOBEC1-
deficient mice, certain editing events were shown to repress protein expression in 
a luciferase reporter assay. To test whether this protein repression was due to 
changes in miRNA processing, HITS-CLIP for the Argonaute (Ago) proteins was 
performed on wild-type and APOBEC1-deficient BMDMs. Although Ago and 
APOBEC1 seemed to target similar transcript substrates, there was little evidence 
for APOBEC1 altering miRNA binding. Overall, in BMDMs APOBEC1 editing 
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events in 3’UTRs can modulate protein expression in a miRNA-independent 
mechanism.  
3.1. BMDM APOBEC1 editing occurs in evolutionarily conserved regions.  
Intestinal APOBEC1-dependent 3′UTR editing, although located in a non-
coding region of the transcript, was identified be largely located in regions of 
substantial phylogenic conservation, implying functional importance to the cell 
(Rosenberg et al., 2011b). In BMDMs, transcript 3′UTRs have been identified 
which contain such a large number of C-to-T editing events; the composite edited 
sequence represents a dramatic change from the genomically-encoded DNA 
sequence. Such abundant editing if located in functional regulatory regions could 
have dramatic downstream consequences. To assess the conservation of BMDM 
APOBEC1 editing, the PhastCon scores of 101nt windows surrounding 
APOBEC1-edited cytosines were compared to random sets of 101nt windows 
located in 3′UTRs. On average, edited windows were significantly (p < 0.01, 
student’s t-test) more conserved than the random windows (Figure 3.1), 
suggesting that sequences edited by APOBEC1 may be functionally relevant. 
 
3.2. Consequences of APOBEC1 editing: luciferase reporter assay.  
As APOBEC1 editing events occur in such conserved regions of transcript 
3’UTRs, I sought to determine whether APOBEC1 editing events in non-coding 
3′UTRs can modulate transcript and protein expression. To assess the effects of 
APOBEC1 on the transcriptome, transcript expression profiles generated from 
RNA-Seq were analyzed, and transcript expression was highly correlated 











Figure 3.1. APOBEC1 editing events occur in conserved regions of 3’UTRs. 
Mean PhastCon score of 100 sets of 68 random 101nt windows in 3’UTRs as 
compared to the mean PhastCon score of the 68 101nt windows surrounding 




















Figure 3.2. Gene expression profiles for wild-type and Apobec1-/- BMDMs. 
Comparison of transcript expression levels as calculated by cuffdiff (represented 
as FPKM, fragment per kilobase per million reads mapped) from RNA-Seq for 




	   	  
transcripts were differentially expressed (Table 3.1), indicating that while 
APOBEC1 editing could be influencing transcript levels of a few downstream 
targets, there were no quantifiable changes in expression of edited transcripts.  
However, the effects of transcript regulatory processes may only be 
appreciable at the protein level. For example, translational repression has been 
shown to be the principal mechanism of miRNA-mediated gene expression 
changes and required for subsequent mRNA degradation (Meijer et al., 2013). 
Therefore, to directly assess the consequences of APOBEC1 editing events on 
protein expression, a standard luciferase reporter assay was utilized. APOBEC1-
targeted transcript 3ʹ′UTRs of interest were amplified from wild-type BMDM 
cDNA and a selection of clones with representative levels of C-to-U alterations 
(either single-site edited or with increasing amounts of hyper-editing) were 
cloned into a dual-luciferase reporter construct. “Edited” (with C-to-U change) 
and “unedited” (with no C-to-U change) luciferase constructs were transfected 
directly into Apobec1-/- BMDMs and the relative change in luciferase expression 
between “edited” and “unedited” constructs was determined (Figure 3.3A).  
A number of these constructs containing C-to-U changes showed 
significant repression of luciferase levels (Figure 3.3B, 3.4), suggesting that 
APOBEC1 editing events can occur in regions important to transcript regulation. 
Of the single-site “edited” constructs tested, only the C-to-U change in Cd36 
modulated luciferase levels (Figure 3.3B). However, the “hyper-edited” 
constructs tested (App, Lamp1, B2m) had a least one clone with a specific 
repertoire of C-to-U changes that reduces protein expression levels in a luciferase 
reporter assay, suggesting that hyper-edited events were more likely to alter 
translational outcomes of targeted transcripts (Figure 3.4). Importantly, these 
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Table 3.1. Genes differentially expressed between wild-type and Apobec1-/- 
BMDMs. Transcriptome-wide mRNA expression data (FPKM; fragments per 
kilobase per million reads mapped) was obtained from RNA-Seq of wild-type 
and Apobec1-/- BMDMs.  Genes listed have significantly lower (top) or higher 
(bottom) expression in APOBEC1-deficient BMDMs as compared to the wild-
type sample.  No significantly differentially expressed genes are edited by 
APOBEC1. 
Gene wild-type FPKM Apobec1    FPKM fold change, log p value
Clk1 37.7471 16.1321 -1.22643 0
Clec7a 58.1322 27.4597 -1.08202 0
Apoe 2576.81 1311.63 -0.974225 4.88E-11
S100a9 47.8244 25.1486 -0.927271 3.51E-08
Atp6v0d2 10.1526 5.40898 -0.908424 2.02E-07
Il7r 16.8209 9.01861 -0.899281 1.99E-10
Kcnj2 15.7805 8.83474 -0.836885 1.90E-10
Lyrm5 9.42068 5.49518 -0.777665 0.00028054
Cysltr1 9.18537 5.37057 -0.774262 1.76E-05
Plxdc2 18.4787 10.8933 -0.762425 1.59E-08
Hpgds 53.2339 31.4061 -0.761298 5.16E-11
Eif2s3y 19.8506 11.7219 -0.759981 1.27E-06
Mrps28 9.30101 15.7603 0.760832 0.000302543
Emp1 79.3218 134.575 0.762617 1.54E-11
Rhof 5.38609 9.20734 0.773546 1.68E-05
Clec4e 9.3831 16.1609 0.78437 5.24E-07
Gm5424 12.1444 21.9633 0.854808 2.22E-08
Smpdl3b 7.35261 13.3654 0.862171 3.18E-07
Hist1h2bc 16.7332 30.4343 0.862989 7.71E-07
Plxnd1 85.3102 159.429 0.902127 7.04E-14
Klf2 27.0208 51.6073 0.933504 5.24E-13
Hist1h1c 26.4887 51.1862 0.950378 2.68E-13
Rsc1a1 7.94624 15.3601 0.950842 2.17E-07
Osgin1 10.5094 20.4214 0.958395 2.07E-10
Fos 37.5034 76.4846 1.02815 0
Gdf3 20.1619 41.9364 1.05657 2.22E-15
Tnf 5.05998 10.5908 1.06561 1.55E-07
Clec4n 3.34772 7.20979 1.10678 3.32E-06
Scd1 3.80326 8.23143 1.1139 5.47E-12
Dusp1 15.8032 34.2969 1.11786 1.33E-15
Ccl2 4.01672 8.85682 1.14077 3.69E-05
Ier3 15.3149 33.8081 1.14243 4.25E-12
Asns 4.5777 10.5256 1.20121 1.39E-09
Apobec1 261.006 601.018 1.20333 0
Irg1 3.01941 8.19314 1.44015 2.10E-13
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Figure 3.3. Consequences of APOBEC1 editing: luciferase reporter assay.
(A) Strategy for testing effects of APOBEC1 3’UTR editing on protein 
expression. (B) Luciferase levels for representative cDNA clones of site-specifc 
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Figure 3.4. Consequences ofAPOBEC1 hyper-editing: luciferase reporter 
assay. Luciferase levels for representative cDNA clones of hyper-edited 
3’UTRs (A) App (B) Lamp1 and (C) B2m, normalized to unedited. Maps of 




	   	  
hyper-edited transcripts tested were generated from cDNA cloning rather than 
targeted mutagenesis and so were reflective of the diversity of transcript 
sequences found in the cell. These results point to a role for APOBEC1 editing 
events, particularly hyper-editing in transcript regulation. However, some 
hyper-edited clones had no effect on protein expression and one singly edited 
clone significantly reduced luciferase levels, indicating that certain APOBEC1-
dependent C-to-U editing events or combinations of C-to-U changes can 
modulate mRNA stability or transcript regulatory factors, but not all C-to-U 
changes alter protein expression.  
 
3.3. Consequences of APOBEC1 editing on endogenous protein levels 
 As APOBEC1 was demonstrated to modulate protein levels in a simplified 
experimental system, I sought to verify this in vivo, looking for endogenous 
protein expression changes in APOBEC1-deficient BMDMs. First, protein levels 
were assessed by Western blot for a selection of targets with publically available 
antibodies. No apparent differences in protein levels could be observed between 
wild-type and APOBEC1-deficient samples. Representative immunoblots for 
APP and B2m proteins are shown in Figure 3.5. Protein level was then evaluated 
via flow cytometry for both cell surface (Figure 3.6A) and intracellular (Figure 
3.6B) APOBEC1 targets. Again, no significant changes in protein levels were 
observed for Apobec1-/- BMDMs. Representative flow cytometry plots are 
depicted in Figure 3.6. Finally, to attempt to detect any subtle changes within a 
specific population of cells that may be mediated by APOBEC1 editing, 
fluorescence-activated cell sorting (FACS) was used to isolate wild-type BMDMs 
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Figure 3.5 Consequences of APOBEC1 editing: Western blotting. Immunoblot 
analysis of B2m (A) and App (B) protein expression in BMDM lysates reveals no 
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Figure 3.6. Consequences of APOBEC1 editing: flow-cytometry. Flow-
cytometry was used to measure the surface expression of CD36 (A) and the 
internal expression of LAMP1 (B) in wild-type (blue) and APOBEC1-deficient 
(red) BMDMs. Two representative histograms are shown, depiciting negiglable 










	   	  
lowest levels (~bottom 10%) of the CD36 receptor. Editing frequencies of the 
Cd36 transcript were then quantified for CD36-high and CD36-low populations. 
However, both populations were approximately 100% edited (data not shown), 
suggesting that transcript editing abundance was not appreciably correlated to 
CD36 expression across a population of wild-type cells. Overall, no changes in 
endogenous protein expression in APOBEC1-deficient BMDMs could be 
observed by Western blot, flow cytometry or FACS analysis. These results 
suggest that APOBEC1-mediated expression changes observed by luciferase 
reporter assay are too subtle to be appreciated endogenously across a population 
of cells.  
 
3.4. Interaction between APOBEC1 editing and miRNA targeting.  
As APOBEC1 editing events in BMDMs occur within highly conserved 
regions of transcript 3′UTRs and can modulate protein expression levels, it is 
possible that APOBEC1 editing could be influencing miRNA targeting. Of note, 
both miRNA binding and APOBEC1 editing have been found to occur 
preferentially in regions of high AU nucleotide composition (Grimson et al., 
2007; Rosenberg et al., 2011b), suggesting that miRNAs and APOBEC1 target 
similar 3’UTR substrates and could be interacting on the same transcripts. To 
investigate the possible consequences of APOBEC1 editing for miRNA targeting, 
high-throughput sequencing of RNA isolated by cross-linking 
immunoprecipitation (HITS-CLIP) of the Argonaute (Ago) proteins (Chi et al., 
2009) was performed in BMDMs derived from wild-type and Apobec1-/- 
littermates (Figure 3.7). The HITS-CLIP protocol was performed in collaboration 
with Emily Conn Gantman of the Darnell lab. BMDMs were UV crosslinked, 
92
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Figure 3.7. HITS-CLIP workflow.  A schematic of HITS-CLIP library preparation 
and bioinformatic analysis is depicted. *CLIP reads are representative not 
quantitative. ***APOBEC1 editing events. 
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RNAse digested and subjected to Ago immunoprecipitation. The RNA in the 
Ago complexes was radiolabeled, purified by gel electrophoresis and then 
visualized by radiography, where two complex sizes were apparent at ~110kDa 
and ~130kDa, corresponding to miRNA and mRNA complexes respectively 
(Figure 3.8A). After proteinase digestion to remove Ago, previously Ago-bound 
mRNA and miRNA pools were reverse transcribed, PCR amplified and subjected 
to ultra high-throughput sequencing. A representative PCR amplification of 
mRNA and miRNA RNA pools is depicted in Figure 3.8B.  
Resultant high-throughput sequencing reads were separated by read 
length into mRNA (≥25nt) and miRNA (≤24nt) pools and aligned to the genome 
(mm9). Expression of miRNAs was highly correlated between wild-type and 
Apobec1-/- (r > 0.99) samples and a list of bound miRNAs was generated from the 
miRNA alignment (Figure 3.9). Ago clusters, or loci with abundant Ago binding, 
were defined as regions with ≥ 5 nucleotide overlap and a total of ≥ 8 mRNA 
reads. The Ago footprint (-30,+32; or more narrowly -24,+22) was extracted from 
the peak of the cluster, and these footprints were normalized to RNA-Seq 
transcript expression, defining the relative “Ago occupancy” of the Ago-bound 
region. High-confidence footprints were defined as occurring in at least 2 
replicates of one genotype (biological complexity of 2 for either wild-type or 
Apobec1-/-). These high-confidence footprints were predominantly located in 
coding regions of transcripts and transcript 3’UTRs (Figure 3.10), a pattern of 
Ago binding previously observed in other applications of Ago HITS-CLIP (Chi et 
al., 2009; 2012; Helwak et al., 2013; Loeb et al., 2012).  
 High-confidence Ago footprints were then intersected with APOBEC1 
editing events to identify regions of Ago-APOBEC1 overlap across the 
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Figure 3.8. Representative HITS-CLIP gels. (A) Autoradiograph of purified 
radiolabeled Ago:RNA complexes.  Regions excised from the nitrocellulose 
membrane are indicated and represent the separate mRNA (blue; ~130kDa) 
and miRNA (red;~110kDa) complexes. (B) Representative DNA gel depicting 
mRNA and miRNA PCR products after linker ligation and PCR amplification. 
mRNA products cover a range of sizes while miRNAs form a distinct band. 






































Figure 3.9. Abundant miRNAs bound to Ago in BMDMs. miRNA 
abundance is plotted as reads per million mapped (RPM) of wild-type 
and Apobec1-/- replicates. The top 10 expressed miRNAs in the wild-type 
samples are labeled. Total biological complexity of each miRNA is indi-









Figure 3.10. Genomic locations of Ago footprints. High-confidence Ago 
footprints were predominantly located in the coding sequence (CDS) 
and 3’UTR of targeted transcripts. All annotations were taken from the 
RefSeq database.  A small number of footprints occured in the 5’UTRs or 
“Other,”which could include: non-coding RNAs, intergenic regions, 
intronic regions or unannotated transcripts. 
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transcriptome (Figure 3.11). APOBEC1 editing events were overrepresented in 
well-covered (20x) Ago footprints by a factor of 5.1 (odds ratio 6.48, 95% 
confidence interval (3.98, 10.21), p = 4.52 x 10-12). However, Ago occupancy levels 
were well correlated between wild-type and Apobec1-/- samples (r = 0.82), with 
negligible differences in occupancy levels between samples in APOBEC1-
targeted footprints, indicating that overall miRNA targeting was not 
dramatically influenced by APOBEC1 binding or editing.  
 
3.5. Consequences of APOBEC1 editing on miRNA targeting.  
To look for more subtle effects on specific miRNAs, I attempted to assign 
miRNAs to APOBEC1-edited footprints and identify regions where APOBEC1 
could create or destroy miRNA seed targets. As has been previously 
characterized in comparable HITS-CLIP experiments, the top-expressed miRNAs 
represented the majority of the miRNA pool (Figure 3.12A). However, when I 
tried to assign only these highly expressed miRNAs to high-confidence Ago 
footprints by canonical miRNA binding rules, many remained “orphan” (Figure 
3.12B). Therefore, to definitively assess APOBEC1:Ago interaction, it was 
necessary to include potential involvement of both lower-expressed miRNAs and 
non-canonical miRNA binding. Based on recent reports characterizing modes of 
miRNA non-canonical binding (Chi et al., 2012; Helwak et al., 2013; Loeb et al., 
2012), the search was expanded to include canonical miRNA seed matches 
(position 2-7 of the mature sequence), as well as non-canonical binding with an 
exact match to the target sequence (binding positions 1-8 or 3-9) and non-









































Figure 3.11. Overlap between APOBEC1 editing events and Ago footprints. 
Ago occupancy values (defined as CLIP read coverage/RNA-Seq read coverage) 
for Ago footprints in wild-type and Apobec1-/- samples. Footprints that contain 




Figure 3.12. Assigning miRNA targets to Ago footprints. (A) Abundance of 
miRNAs plotted as the fraction of the total miRNA reads mapped. The few 
highest “expressed” miRNAs (>1000RPM) make up ~98% of the total reads 
mapped. (B) Fraction of Ago footprints that were “orphan” (no canonical 
miRNA seed match) when searched for miRNA at various abundance (RPM) 
cut-offs. miRNA abundance levels were calculated as number of CLIP reads 
that mapped to the mature miRNA sequence per million mapped.  A series of 
lists of miRNAs were created based on abundance with cut-offs at 10, 50, 100, 
500, 1000, 2000 and 5000 RPMs, with decreasing numbers of miRNAs at each 
cut-off.  The footprints were scanned for the canonical miRNA target regions 
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Figure 3.13. Putative miRNA seed targets in APOBEC1-edited regions. 
“Edited” (with APOBEC1-dependant C-to-T change) and “Unedited” (without 
editing events) footprint sequences were scanned for expressed miRNA targets 
regions (“canonical” = match to position 2-7 of the mature miRNA, “non-
canonical match” = match to positions 1-6 or 3-8). miRNA targets which would 
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Figure 3.14. Testing APOBEC1-edited miRNA seed targets by luciferase assay. 
(A) Luciferase reporter strategy. APOBEC1 editing events were introduced via 
site-directed mutagenesis and tested for effect on miRNA-targeting via luciferase 
reporter assay.  (B) Luciferase reporter assays yielded no significant luciferase 
expression differences between “edited” and “unedited” constructs. 
APOBEC1-targeted transcripts
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mismatch or G-bulge insertion). From this analysis, an APOBEC1-targeted 
footprint map was created, identifying putative miRNA binding sites in each 
footprint, and identifying those, which overlapped with an APOBEC1 editing 
event (Figure 3.13). Using the narrowest definition of the Ago footprint (46nt), a 
set of putative miRNA target regions for each footprint was established after 
filtering for miRNAs which were expressed in 3 replicates and whose target 
regions was within a distance of 50 nucleotides from the center of the Ago peak. 
For each footprint we identified a set of likely miRNA targets, a number of which 
were disrupted or created by APOBEC1 editing events (Figure 3.13).  
I used a luciferase reporter assay to test the functionality of potential 
APOBEC1-altered miRNA binding sites. Identified 3ʹ′UTRs were cloned into a 
dual-luciferase construct and site-specific mutagenesis was performed at the 
location of APOBEC1 editing events that had been observed in Ago-CLIP to 
potentially disrupt or enhance miRNA binding (Figure 3.13, Figure 3.14A). 
Constructs containing five individual C-to-U mutations identified to disrupt a 
miRNA seed target were tested with luciferase reporter assay and failed to alter 
luciferase levels (Figure 3.14B). These results demonstrate that while APOBEC1 
editing events can modulate protein expression, this phenomenon is unlikely 








	   	  
Chapter 4: Discussion  
 
The use next-generation sequencing has greatly expanded the editing 
repertoires of RNA editing enzymes, ADAR and APOBEC1. In particular for 
APOBEC1, our lab used a comparative RNA-Seq screen to identify 32 additional 
mRNA targets contained in transcript 3’UTRs, pointing to additional functions 
for APOBEC1 that had been previously unappreciated. Based on the observation 
that APOBEC1 was expressed in immune cell types, I decided to use 
comparative RNA-Seq to identify novel APOBEC1 editing events in BMDMs. 
The RNA-Seq screen revealed abundant APOBEC1 dependent mRNA editing in 
BMDMs in highly-conserved regions of transcript 3’UTRs. These newly 
identified APOBEC1 editing events occurred in two distinct patterns: site-specific 
editing and hyper-editing. Further analysis revealed that these editing events 
shared adjacent nucleotide preferences with intestinal APOBEC1 editing events 
but were only loosely associated with a downstream mooring sequence, 
previously demonstrated to be essential for APOBEC1 editing of Apob and 
associated with intestinal 3’UTR editing. Although differences in endogenous 
transcript and protein levels were not observed, certain patterns of editing 
resulted in altered luciferase activity via standard luciferase reporter assay, 
suggesting that in some cases editing can alter transcript fate. Finally, 
transcriptome-wide profiling of miRNA binding sites revealed little functional 
overlap between miRNA targeting and APOBEC1 editing events in 3’UTRs, 
pointing to a miRNA-independent mechanism for APOBEC1-mediated 
transcript regulation. Below I will discuss the questions remaining about the 
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implications for ACF-independent APOBEC1 site-specific and hyper-editing 
events in transcript 3’UTRs.  
 
4.1 Overestimation of false-positive rate 
Here we used a comparative RNA-Seq screen in BMDMs to identify the 
first examples of APOBEC1 physiological editing outside of the digestive system. 
We identified over 100 high-frequency editing events, more than tripling the 
number of previously established APOBEC1 substrates. A subset of these 
APOBEC1-dependent C-to-U changes was validated with standard Sanger 
sequencing with a false positive rate (FDR) of 12.5%. The implied false-positive 
rate was calculated at less than 1% based on the amount of C-to-U editing 
identified in the APOBEC1-deficient samples that was absent from the wild-type 
sample, indicating that this FDR may be an overestimate. This overestimation 
may have occurred for a few reasons. First, I chose to forgo a genomic SNP filter 
during the post-screen filtering process. This choice was based on an observation 
I made during the validation of the Rosenberg data early in my thesis work. One 
target, Cd36, was not identified in the initial comparative RNA-Seq screen. 
However, Cd36 was found to have a strong mooring sequence, and its mRNA 
transcript sequence was later determined to be highly (> 90%) edited by 
APOBEC1. I subsequently realized that this specific C-to-U edit was included in 
a SNP database, based on sequencing that had been performed on a cDNA 
substrate. As highly edited targets are more likely to have been previously 
identified as SNPs, I decided to abandon the SNP filter and validate a subset of 
the editing targets with close to 50% or 100% editing and throw out sites with 
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50% or 100% editing in coding regions. One site in a coding region, which was 
included in the FDR calculation, was thrown out.  
Additionally, analysis of the APOBEC1 editing events has revealed that 
there may be some plasticity in the editing repertoire, leading to unvalidated 
editing events. For example, the two identified sites within the Rhoa transcript 
3ʹ′UTR could not be confirmed via subclone sequencing, but further analysis of 
the transcript sequence revealed a set of additional low frequency APOBEC1-
dependent C-to-U editing events (data not shown). This result suggests that 
identification of the full spectrum of possible APOBEC1 editing events would 
require the compilation of transcript-wide sequencing of many samples. 
 
4.2 APOBEC1 editing is predominantly restricted to 3’UTRs  
Through an established RNA-Seq screen, I have identified over 100 novel 
APOBEC1 editing events in 3’UTRs, but no additional APOBEC1-catalyzed 
events within transcript 5’UTRs or coding regions. To date, the only 
physiological APOBEC1 editing event occurring in a coding region is the editing 
of C6666 in Apob transcript, where the majority of editing serves an important 
role for lipid metabolism and transport. Previously we established that while the 
APOBEC1 “mooring sequence” could be found in the coding region of a set of 
other expressed transcripts, but no APOBEC1 editing was observed at these loci. 
Taken together, these data suggest that Apob is the only known APOBEC1 
editing event that alters a codon, and the remainder of APOBEC1 editing is 
restricted to transcript 3’UTRs. The reasons for this remain elusive. Possibly, 
APOBEC1 editing in 3’UTRs is “sacrificial,” absorbing aberrant potentially 
harmful editing activity in a safe region of the transcript where editing will have 
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a minimal effect on final protein composition. This hypothesis is somewhat 
logical for intestinal APOBEC1 activity, in which there is one highly important 
editing event in a coding region. Theoretically other coding regions could be 
protected from APOBEC1-mediated editing by allowing 3’UTRs to be edited and 
limiting the amounts of free APOBEC1 not bound to Apob. However, in immune 
cells where there is no established role for APOBEC1 this is less plausible, 
making it more likely that 3’UTR editing fills an important role in this cell type.  
Prior to the identification of APOBEC1 editing in 3’UTRs, it was 
postulated that access to most coding exons for the large multi-protein editosome 
was blocked by RNA-splicing machinery. APOBEC1 editing in Apob occurs in 
the middle of an exceptionally large exon (> 7kb), perhaps avoiding the RNA 
splicing machinery localized to distant exon-intron boundaries (Sowden et al., 
1996b). This mechanism could explain the abundant APOBEC1 editing found in 
untranslated regions. Additionally, APOBEC1 could be recruited by an 
alternative RNA-binding factor, which is exclusively targeted to 3’UTRs. As 
3’UTR editing seems to occur most abundantly in a cell type that lacks ACF, a 
model in which APOBEC1 3’UTR editing occurs in the absence of ACF but under 
the influence of another auxiliary factor is appealing. Further analysis of specific 
targeting factors and the influence of exogenously introduced ACF on BMDM 
editing could provide insight into some of these questions.  
Additional mechanisms mediating APOBEC1 3’UTR editing might 
involve a specific cellular factor that protects coding exons from APOBEC1 
editing, potentially by targeting edited transcripts for degradation. Indeed, 
APOBEC1 editing of C6666 in Apob introduces a premature stop codon, making 
it a target for the nonsense-mediated decay (NMD) pathway. The edited 
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transcript escapes NMD by remaining in complex with the APOBEC1 editosome 
as it is exported from the nucleus. Interestingly, this process requires ACF 
involvement; edited Apob transcripts associated APOBEC1 alone are subject to 
NMD but transcripts bound to an APOBEC1:ACF complex are protected 
(Chester et al., 2003). As such, in ACF-deficient BMDMs, some catastrophic 
editing events occurring in coding regions may be degraded via NMD, and elude 
detection via RNA-Seq. However, silent or non-synonymous mutations that alter 
codon specificity but do not introduce a stop codon should be unaffected by 
NMD. As none of these types of mutations have been observed in BMDMs, 
NMD cannot be the only protective factor against APOBEC1 editing in coding 
exons.  
Lastly, APOBEC1 editing of the Apob transcript is associated with a 
specific transcript secondary structure, a conserved stem-loop that serves to 
introduce the edited cytidine into the APOBEC1 catalytic pocket. 3’UTRs are 
associated with abundant secondary structure, indicating that they might 
naturally serve as APOBEC1 substrates. This is reminiscent of ADAR editing 
where inverted repeats in 3’UTRs provide the optimal dsRNA substrate for 
ADAR editing. Duplexes in coding regions require more complex binding with a 
complementary intronic region and occur at much lower frequency, partially 
explaining why ADAR editing is overrepresented in transcript 3’UTRs. A similar 
mechanism could be influencing APOBEC1 editing, shifting the known 





	   	  
4.3. Implications for APOBEC1 hyper-editing  
Identification of BMDM-specific APOBEC1 RNA editing revealed two 
distinct editing patterns that I have termed single-site editing and hyper-editing. 
Single-site editing events are reminiscent of the canonical physiological ApoB 
editing and most APOBEC1-dependent editing events identified in the intestine 
transcript 3′UTRs: one major editing site, edited at a high frequency, occasionally 
associated with nearby low frequency C-to-U editing events. We were surprised 
to discover dramatic APOBEC1 hyper-editing activity in BMDMs, an unusual 
physiological behavior for APOBEC1. As discussed, there is some background 
activity for APOBEC1 observed in Apob (Blanc et al., 2012) and 3’UTR targets in 
enterocytes (Rosenberg et al., 2011b). This editing was typically very low 
frequency (< 10%) and occurred in association with one highly edited site. In 
contrast, there are a few previous examples of more high-frequency APOBEC1-
dependent promiscuous or hyper-editing activity observed in the ApoB transcript 
(Sowden et al., 1996b; 1998; Yamanaka et al., 1996) and in viral transcripts(Petit et 
al., 2009), but this editing behavior occurs in the context of APOBEC1 over-
expression or MLV infection and does not represent the physiological editing 
behavior of a steady-state cell. Is there a difference between this higher frequency 
“ hyper-editing” we observe and background editing found in Apob? Why in 
some transcripts is there one dominant site-specific event and in other transcripts 
targeting seems seem to be promiscuous and plastic? The mechanisms of 
APOBEC1 hyper-editing in BMDMs and how certain transcripts are targeted for 
site-specific editing versus hyper-editing remain elusive. The possible 
contribution of an additional co-factor in lieu of ACF is discussed below. 
Regardless of mechanism, APOBEC1 hyper-editing results in a dramatic shift in 
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the RNA sequence, increasing the likelihood that editing could be affecting 
important regulatory regions of the UTR.  
 
4.4. ACF-independent APOBEC1 editing  
APOBEC1 editing activity in BMDMs is especially intriguing because it 
occurs in the absence of ACF and is only loosely associated with the downstream 
11-nucleotide mooring sequence. These results suggest that the mechanism of 
APOBEC1 editing in BMDMs may differ considerably to that established for 
ApoB. Interestingly, while as a unit recombinant APOBEC1 and ACF were shown 
in vitro to be necessary and sufficient to induce C-to-U editing at C6666 in ApoB 
(Lellek et al., 2000; Mehta et al., 2000), no study has shown in vivo that ACF is 
essential for APOBEC1 editing. In the intestine, these studies have been 
complicated by the difficulties in generating an ACF-deficient mouse, as 
disruption of the ACF locus leads to embryonic lethality (Blanc et al., 2005). Our 
data definitively show that physiological APOBEC1 enzymatic editing activity 
occurs in 3′UTRs in the absence of ACF.  
Although we have shown that APOBEC1 can edit mRNA transcripts 
without ACF, the mechanism by which this occurs is still an outstanding 
question. Some in vitro studies suggest that under specific elevated temperature 
conditions APOBEC1 may be capable of ACF-independent editing (Chester et al., 
2004), indicating that in certain environments it could be the sole mediator of 
both RNA targeting and editing. Indeed, in transgenic APOBEC1-overexpressing 
mice, a proposed mechanism for the observed hyper-editing activity is that the 
ACF:APOBEC1 stoichiometry is shifted, and the abundant levels of free 
APOBEC1 aberrantly edits the Apob transcript (Blanc and Davidson, 2010; 
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Chester et al., 2004). Presumably, any alternative co-factor would also be 
overwhelmed by the over-expression of APOBEC1, pointing to independent 
APOBEC1 activity in this non-physiological system. Alternatively, APOBEC1 
editing in BMDMs could be happening in conjunction with another auxiliary 
factor, potentially one or more candidate members of the multimeric editosome, 
many of which are expressed in BMDMs based on RNA-Seq transcript 
expression, including ABBP-1, ABBP-2, CUGBP2, and GRY-RBP (data not 
shown). Furthermore, it is also a point of debate whether APOBEC1 is capable of 
nuclear import when not in complex with ACF (Yang et al., 2001), suggesting 
that APOBEC1 cytoplasmic-nuclear shuttling may need to occur in complex with 
an associated protein, underscoring the importance of some sort of associated 
editosome.  
Regardless of mechanism, the fact that APOBEC1 editing occurs without 
ACF in 3’UTRs brings up questions about the necessity of ACF involvement of 
other APOBEC1 targets. As described above, APOBEC1:ACF complexes were 
only shown to be essential for editing in vitro, and only for C6666 in the Apob 
transcript. Whether ACF is necessary for editing in alternative sites in apoB or 
intestinal 3’UTR targets is unclear. BMDMs and intestinal enterocytes share a 
number of APOBEC1 targets, indicating that at least some examples of 3’UTR 
editing in small-intestinal enterocytes might occur without ACF involvement.  
 A popular hypothesis in the field, based largely on the over-expression 
phenomenon observed in mouse models, is that ACF primarily acts as a 
“chaperone,” limiting aberrant APOBEC1 editing. This is somewhat supported 
by an increase in APOBEC1 editing frequency observed in heterozygous A1cf+/- 
mice (Blanc et al., 2005). The abundant APOBEC1-mediated hyper-editing in 
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BMDMs also lends support for the idea that APOBEC1 might edit more 
promiscuously without ACF. However, additional examples of site-specific, 
seemingly strictly targeted editing are also prevalent in BMDMs, complicate the 
idea that APOBEC1 would require ACF for targeted mutation. Overall, the 
discovery of high frequency APOBEC1 RNA editing in BMDMs dramatically 
expands the role for APOBEC1 beyond the digestive system and brings up many 
questions about precise mechanisms of APOBEC1 editing in 3′UTRs. As they 
express APOBEC1 and lack ACF, BMDMs provide an ideal experimental system 
to further investigate the influence of cofactors on APOBEC1-dependent RNA 
editing.  
 
4.5. APOBEC1 editing can modulate protein expression  
In BMDMs, APOBEC1 editing events occurred more frequently than 
expected by chance in regions conserved by evolution, suggesting functional 
relevance. When the specific translational outcomes of APOBEC1-dependent C-
to-U editing events in 3′UTRs were assessed via luciferase reporter assays, 
examples of C-to-U changes were observed that led to significant reduction in 
luciferase activity. As hyper-edited transcripts tested were generated from 
directly from cloned cDNA they reflected the variation in transcript sequences 
found in the cell. In general, the majority of clones with one or two C-to-U 
changes had no consequence for luciferase expression whereas hyper-edited 
transcript 3′UTRs were more likely to result in differential translation outcomes. 
However, some hyper-edited clones had no effect on protein expression and one 
singly edited clone, Cd36, significantly repressed luciferase levels. These results 
suggest that certain combinations APOBEC1-dependent C-to-U editing events or 
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combinations of C-to-U changes can affect protein expression but random C-to-U 
changes alone are not sufficient to yield altered translational outcomes. 
Importantly, these experiments were performed in APOBEC1-deficient cells and 
therefore only tested the effects of C-to-U changes on the transcript sequence 
itself, not other modes of APOBEC1-mediated regulation that could occur via 
RNA-binding.  
An important aspect of these luciferase reporter assays is that they were 
performed in the primary cell type of interest, BMDMs. As BMDMs are resistant 
to lipofectamine and similar transfection modalities, I used Amaxa 
“nucleofection” technology to introduce reporter constructs into the nucleus 
through electroporation. This efficiently (~20%) introduced luciferase constructs 
into BMDMs although led to substantial cell activation. Therefore, a caveat of 
these experiments is that they occur in an activated setting rather than a steady-
state cell where editing events were originally identified.  
Interestingly, a large part of my initial work in the lab involved luciferase 
reporter assays designed to test the translational outcomes of APOBEC1 
intestinal 3’UTR targets. These experiments were performed in 293Ts and 
yielded no significant luciferase expression differences in edited constructs as 
compared to unedited controls (data not shown). Of note, in establishing a 
BMDM system to look for luciferase changes, I used one of these previously 
cloned constructs, Cd36, a highly edited target in both the intestine and BMDMs. 
In contrast to the assays performed in 293Ts, the Cd36 edited construct when 
transfected into BMDMs, exhibited significant luciferase repression. This result 
highlights the limitations of luciferase reporter assays performed in unassociated 
cell lines, a commonly used experimental method. Cell-specific expression of 
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miRNAs, RNA-binding proteins, and other auxiliary factors that substantially 
affect transcript regulation and the specific expression profiles may vary widely 
between cell-types, especially for transformed cells with uncertain karyotypes.  
 Despite the ability of “edited” 3’UTRs to alter protein expression in a 
luciferase reporter assay, no transcript level differences were observed for 
targeted transcripts and no protein expression could be appreciated by standard 
assays. This is not completely surprising, as changes to translational efficiency or 
subtle changes in transcript stability may not be appreciable at the transcript 
level. Additionally, the predominantly two-fold protein expression differences 
we observe are likely below the threshold of Western blotting and flow-
cytometric analysis, the two techniques utilized.  
 
4.6. HITS-CLIP reveals little interaction between miRNA targeting and 
APOBEC1 editing. 
MiRNAs preferentially target phylogenically conserved regions of 3′UTRs, 
which are also the principle sites of APOBEC1 editing in BMDMs. To 
comprehensively assess the interaction of APOBEC1 editing with miRNA 
targeting, we used HITS-CLIP to generate both a list of miRNAs expressed in 
BMDMs and a transcriptome-wide map of Ago binding in wild-type and 
Apobec1-/- cells. As described above, we exhaustively searched for miRNA seed 
targets within regions of Ago-binding that might be affected by APOBEC1 
editing events. Even with such a comprehensive search for miRNA targets, Ago 
HITS-CLIP analysis revealed significant overlap between regions of Ago 
targeting and APOBEC1 editing events, but little evidence for miRNA target 
creation or disruption by APOBEC1 editing. Some editing events shown to 
114
	   	  
repress luciferase expression, such as the high frequency event in the Cd36 
transcript, did not overlap with a region of Ago binding, suggesting that 
APOBEC1 editing was affecting other mechanisms of transcript regulation. Other 
hyper-edited transcripts that repressed protein expression levels contained 
editing events that overlapped with sites of Ago binding, but no miRNA sites 
generated by APOBEC1 editing events could be identified. All other potential 
sites of APOBEC1:Ago interaction, including potential miRNA target generation 
in App, could not be validated by luciferase reporter assays, suggesting that the 
identified miRNA site was non-functional, or that the C-to-T change had 
negligible effect on the efficiency of miRNA repression. Despite this, we cannot 
definitively rule out a role for miRNAs in APOBEC1-mediated transcript 
regulation. Lower frequency combinations of events could lead to more subtle 
changes below the resolution of HITS-CLIP or unappreciated modes of miRNA 
binding could be mediating some of the protein expression differences. In 
particular, a recent study used an adapted HITS-CLIP technique to link and then 
sequence interacting mRNAs and miRNAs (Helwak et al., 2013). Although this 
process was quite inefficient, the authors are able to construct a profile of the 
many forms of predicted miRNA binding, the majority of which requires 
additional binding events beyond the canonical seed (positions 2-7 of the mature 
miRNA). This work has substantial limitations as it was performed using an 
ectopically expressed tagged Ago protein in a human cell line, but it points to the 





	   	  
4.7. Alternative mechanisms for APOBEC1-mediated transcript regulation  
While the majority of APOBEC1 editing events in BMDMs do not seem to 
affect miRNA targeting, the specific mechanism for APOBEC1 editing-mediated 
protein repression remains unclear. As has been discussed above with RNA 
editing, next-generation sequencing has greatly expanded the breadth of 
knowledge regarding the complexity of RNA modification and regulation. Most 
importantly for this discussion, cis-acting elements in transcript 3’UTRs and 
trans-acting factors that bind to them have been shown to contribute to transcript 
regulation through a variety of mechanisms, a number of which could be 
influenced by RNA editing.  
Specific ADAR editing events in 3′UTRs have been implicated in targeting 
transcripts for cleavage via a specific nuclease (Scadden, 2005) and inducing 
nuclear retention by promoting binding to a dedicated nuclear factor (Chen and 
Carmichael, 2009; Prasanth et al., 2005; Zhang and Carmichael, 2001). The caveats 
for these hypotheses have been discussed in Section 1.2.5, but they remain 
popular models for the regulation certain ADAR-targeted transcripts. Similarly, 
APOBEC1 editing in 3’UTRs could target the transcript for degradation or result 
in its retention in the nucleus. However, there seems to be negligible transcript 
expression differences between wild-type and APOBEC1-deficient samples, and 
no edited transcripts exhibit differential expression between the two genotypes. 
This result detracts from the degradation hypothesis, in which expression 
changes should be appreciable at the transcript level. Recent work in our lab also 
points against the nuclear retention of APOBEC1 edited transcripts. Transcripts 
isolated specifically from the nucleus tended to have lower editing frequencies 
than those extracted from the cytosol and there is no differences in nuclear of 
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cytosolic transcript expression between wild-type and APOBEC1-deficient 
BMDMs. This work is still in progress, but points to the efficient nuclear export 
of APOBEC1 edited transcripts. Together, these data suggest that unlike ADAR, 
APOBEC1-mediated transcript regulation is not occurring via nuclear retention 
or cleavage. Furthermore, as we have observed that edited transcripts are 
efficiently exported from the nucleus, the regulation of these transcripts most 
likely occurs in the cytoplasm and is not associated with changes in splicing, 5’-
capping and alternative polyadenylation. Indeed, analysis of RNA-Seq reads 
reveals no differentially expressed isoforms or alternative polyadenylation sites 
in edited transcripts between wild-type and APOBEC1-deficient samples, further 
underscoring this point.  
Alternatively, APOBEC1 editing could be altering transcript stability, 
potentially by modulating the binding properties of stabilizing or de-stabilizing 
RNA-binding proteins. AU Rich Elements (AREs), which consist of sets of 
AUUUA pentamers, are bound by a variety of RNA-binding proteins and the 
number of AREs in a transcript is inversely correlated with transcript stability 
(Hao and Baltimore, 2009). As APOBEC1 introduces C-to-U changes within AU-
rich regions of 3’UTRs, it seems likely that APOBEC1 editing could introduce 
AREs. However, none of the targets shown to be differentially expressed via 
luciferase reporter assay have AREs introduced by C-to-U editing events. This 
indicates that, while APOBEC1 editing could be influencing stability via another 
mechanism, AREs are not likely to mediate this control. Alternatively, APOBEC1 
itself has been shown to mediate transcript stability through its RNA-binding 
capabilities (Anant and Davidson, 2000; Anant et al., 2004), pointing to potential 
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editing and RNA-binding mechanisms involved in APOBEC1 regulation of 
transcript stability.  
There are a variety of other mechanisms in which APOBEC1 could be 
influencing transcript regulation but as in the above these mainly involve 
modifying 3’ UTR cis-elements and leading the altered functions of RNA-binding 
proteins (RBPs). In this way, structural elements within transcript 3’UTRs can 
also influence protein expression. For example, in response to environmental 
cues an RNA secondary structure in the Vegfa transcript 3’UTR undergoes a 
conformational change that regulates a RBP-mediated change in VEGFA protein 
expression (Ray et al., 2009). As Apob editing requires a stem-loop structure, it 
seems likely that 3’UTR editing occurs in the vicinity of secondary structure and 
that base-pairing within structural elements could be disrupted by editing. 
Additionally, mRNA subcellular localization can be mediated by specific “zip 
codes” within transcripts 3’UTRs; these motifs are bound by RBPs that mediate 
the targeting of the mRNA to a precise cytoplasmic environment. This 
asymmetric localization of mRNAs generates cell polarity by controlling the sites 
of translation. A zip code mechanism of subcellular localization has been 
specifically characterized in neurons and fibroblasts, where β-actin mRNA 
transcripts are localized to the fibroblast leading edge (Kislauskis et al., 1994) and 
neuronal growth cones (Bassell et al., 1998), promoting accumulation of β-actin 
protein and subsequent forward movement. Intriguingly, this subcellular 
localization is partially mediated by KSRP, a known inhibitor of APOBEC1 (Gu 
et al., 2002), but no further link between RNA editing and subcellular localization 
of this manner has been established.  
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While there are many modes of potential APOBEC1-mediated regulation 
of gene expression, the lack of observed transcript expression differences in 
APOBEC1-deficient cells points to a mechanism in which APOBEC1 editing 
more directly affects translational efficiency, potentially by modulating the 
binding properties of RBPs and repressing translation through a variety of 
potential mechanisms including de-adenylation, ribosome stalling or other 
modes of inhibition of translational machinery. To test this hypothesis, we plan 
to conduct ribosomal profiling of APOBEC1-deficient BMDMs.  
 
4.8 Closing remarks  
 This thesis presents a body of work that establishes abundant 
physiological APOBEC1 editing activity beyond the digestive system and 
demonstrates that these untranslated editing events can modulate protein 
expression. These findings are highly significant to the fields of RNA editing and 
transcriptional regulation. First, we demonstrate APOBEC1 catalytic activity in 
an immune cell type, the first time physiological APOBEC1 editing activity has 
been characterized outside of the digestive system. This editing also occurs in the 
absence of the “essential” APOBEC1 co-factor, calling into question the dogma 
regarding the regulation and editing mechanism of this highly characterized 
RNA-editing enzyme. Additionally, APOBEC1 hyper-editing, observed in a 
number of transcripts in BMDMs, represents a unique editing modality for 
APOBEC1. Finally, we establish a role for APOBEC1 editing in BMDM transcript 
3’UTRs in the regulation of transcript expression through a non-miRNA-
mediated mechanism.  
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Although we have definitively shown that C-to-T changes at the sites of 
APOBEC1 editing can led to protein expression differences in a simplified 
experimental system, analysis of the downstream consequences of APOBEC1 
editing in vivo presents a significant challenge. Targeted transcripts contain 
editing events with editing frequencies that range from 20-80% and hyper-edited 
transcripts can contain thousands of combinations of editing events and editing 
frequencies. The editing repertoire of APOBEC1-targeted transcript 3′UTRs 
present in a cell at any given moment could be vast, making the resolution of any 
specific event difficult to assess over a cell population. Therefore although it 
seems that APOBEC1 editing can have effect on individual transcript fate, 
further study is required to definitively assess the specific mechanisms behind 











	   	  
Chapter 5: Materials and Methods  
5.1. Materials and methods for the identification of mRNA editing in BMDMs 
5.1.1 Mice and isolation of BMDMs 
C57BL/6 littermate or age-matched mice were used at 6-12 weeks of age. 
Apobec1-/- mice were generated as previously described (Hirano et al., 1996) and 
provided by N. Davidson (Washington University School of Medicine, St. Louis, 
MO). Apobec1-/- mice are healthy, viable and need no specific husbandry. To 
isolate BMDMs, mice were euthanized by cervical dislocation and the hind leg 
removed and cleaned of hair, skin and muscle. The bare bone was cleaned with a 
70% EtOH. The two ends of the femurs were cut and the marrow was flushed 
with 22G needle with cold PBS onto a cell strainer. The cells were pelleted and 
resuspended in macrophage media (DMEM, 10% FBS, 1% Non-essential amino 
acids (Invitrogen), 0.1% BME, 20ng/mL M-CSF (Peprotech)) and plated onto one 
untreated 10cm and incubated in a Precursor cells were plated onto untreated 
10cm dishes and incubated in humidified 37°C/5% CO2 incubator overnight. On 
day 2, cells were counted and re-plated at a concentration of 2 million cells per 
10mL macrophage media onto untreated 10cm dishes. Cells were matured for 7 
days in, replacing half of the media (with macrophage media supplemented with 
40ng/mL M-CSF) every 3 days. Macrophage surface markers: F4/80 (Invitrogen) 
and Cd11b (BD biosciences) were confirmed via flow cytometry on a FACS 





	   	  
5.1.2. RNA extraction and amplification of Apobec1, A1cf and Apob.  
BMDMs were washed with cold PBS and RNA was extracted with either 
Trizol (Invitrogen) or an RNAeasy kit (Qiagen). RNA was normalized and then 
subjected to DNAse treatment with RQ1 RNAse-free DNAase (Promega). 
Reverse transcription was performed with SuperScript III (Invitrogen) and either 
oligo-dT primers, transcript-specific primers or random hexamers, depending on 
the experiment in question (described below).  
 
For RTPCR analysis of APOBEC1 expression: cDNA was generated using oligo-dT 
primers. Target specific primers were designed to amplify a 200bp region of 
APOBEC1, ACF, ApoB and GAPDH. PCR amplification was performed with a 
Hot-Start Taq Polymerase (Qiagen) and amplicons were run on a 1% agarose gel 
and visualized.  
 
For qRTPCR analysis of APOBEC1 expression: cDNA was generated using random 
hexamers. Target-specific primers were designed to amplify a 100bp exon-
spanning region of APOBEC1 and a 100bp exon-spanning region of an 
endogenous control, Rpl32 or GAPDH. qRTPCR was performed using the Sybr 
Green Master Mix (Life Technologies) and run on a Roche Life cycler 480 system.  
 
5.1.3. LPS stimulation.  
BMDMs were derived as described above and then plated onto untreated 
6-well plates. Cells were stimulated with 100ng/uL of LPS (Sigma) for 0, 2, 6, 12, 
and 24 hours. At each time-point, RNA was extracted with the RNAeasy 
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(Qiagen) kit and cDNA was derived as described above with random hexamer 
primers. qRTPCR was performed as described above.  
 
5.1.4. mRNA-Seq library preparation 
mRNA-Seq library preparation was adapted from standard Illumina 
protocols. RNA was extracted from macrophage cultures using the Ribopure kit 
(Ambien). DNAse treatment was performed with Turbo DNAse (Ambien). RNA 
quality was determined by Bioanalyzer analysis (Agilent Bioanalyzer) and only 
high quality RNA preps were used for sequencing. RNA was diluted to 10ug in 
50uL and poly-A+ selection was performed with Sera Mag oligo-dT magnetic 
beads (Thermo), RNA was eluted off the beads with 10mM Tris and analyzed for 
quality with a Bioanalyzer (Figure 5.1B). All eluted mRNA was fragmented with 
fragmentation buffer (final composition: 40 mM Tris acetate, pH 8.2, 100 mM 
potassium acetate, 30 mM magnesium acetate) in a PCR thermocycler at 94°C for 
4 min 45s. RNA was washed and concentrated by ethanol precipitation 
(performed with 5M sodium acetate, pH 5.2 and 100% ethanol) and was 
analyzed for quality on a Bioanalyzer (Figure 5.1C).  
First strand synthesis was performed using a SuperScript III first-strand 
synthesis system kit (Invitrogen) and was primed with random primers. Second 
strand synthesis was performed with the Superscript double-stranded cDNA 
synthesis kit (Invitrogen), which utilizes E. coli DNA ligase (10U/uL), E. coli 
DNA polymerase (10U/uL) and E. coli RNAse H (2U/uL). After double-stranded 
synthesis, ends were repaired using dNTPs, T4 DNA polymerase, Klenow DNA 
polymerase and T4 PNK (All provided by Illlumina). End-repaired cDNA was 
purified in a PCR purification kit (Qiagen) and eluted in provided EB buffer.  
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To facilitate PCR adaptor ligation, additional adenosines were added to 
the 3′ ends of the double-stranded cDNA (ds-cDNA) using Klenow exo (3′ to 5′ 
exo-) in the presence of dATP (both provided by Illumina). Illumina PCR 
adaptors were ligated to the ds-cDNA using T4 DNA ligase (Illumina) and 
cDNA templates were purified by gel electrophoresis on a 2% agarose gel and 
gel extraction. Fragments that ran from 275-325bp were excised from the gel and 
DNA was extracted using a gel extraction kit (Qiagen) and eluted in provided EB 
buffer.  
Purified cDNA templates were enriched with 15 cycles of PCR 
amplification using Illumina PE 1.0 and 2.0 primers and amplified with Phusion 
DNA polymerase (Qiagen). The concentration and quality of final amplified 
libraries was determined by Nanodrop spectrophotometer and Bioanalyzer 
analysis.  
 
5.1.5. RNA-Seq: sequencing, read processing and alignment  
 
 Single-end 75nt sequencing was performed on Illumina Genome Analyzer 
IIx (GAIIx) yielding 28-33 million reads. Initial read quality and trimming was 
performed with the Fastx toolkit software package (available at 
http://hannonlab.cshl.edu/fastx_toolkit/index.html). Read quality was 
analyzed with the Fastx quality stats tool, which revealed a C/T bias at the first 
base of the reads. Subsequently, the first base was trimmed using the Fastx 
trimmer tool.  
Trimmed reads were mapped to the C57LBL/6 mouse reference genome 
(NCBI37/mm9) using Tophat (v1.3.3) and Bowtie(v0.12.8) (Trapnell et al., 2009) 
with the parameters “--solexa1.3-quals -g 1 --coverage-search.” The details of the 
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alignment parameters are as follows: -g 1 suppresses alignments for reads that 
map to more than 1 location in the reference genome; --coverage-search enables a 
coverage-based search for junctions and it recommended for read 75bp or higher. 
The default number of mismatches to the reference genome was used, 2/25b 
segment or up to 6/ 75bp read.  
 
5.1.6. Identification of APOBEC1 dependent C-to-U mismatches from mRNA-
Seq  
Pileups were assembled using SAMtools (v0.1.7a). Filters for non-editing 
SNVs, as described in the text, were implemented with a custom Python script 
and editing events were visualized with IGV (Robinson et al., 2011; 
Thorvaldsdóttir et al., 2013). C-to-T (in positive transcripts) or G-to-A (in 
negative transcripts) mutations occurring at a frequency of 20% in at least 20 
reads in the wild-type sample or occurring at a frequency of 10% in 5 reads for 
the APOBEC1-deficient sample were first identified from SAMtools pileups. 
Then, these putative sites were put through a series of filters to remove false 
positives. Specifically, sites were retained if they occurred in the UCSC known 
gene database, did not occur exclusively in one strand, were more than 50nt from 
another non C-to-T mutation and were not in the non-isogenic region. The non-
isogenic region was determined as the range of putative “editing events” that 
occurred in the KO sample in chromosome 6. For this experiment is was defined 
as chr6:56829100-137411200. Real editing events occurring in this relatively large 
region would be removed from any screen, but as this region is highly variable it 
is impossible to discern true APOBEC1 editing events from SNPs without 
considerable standard Sanger sequencing validation. Finally, the SNVs identified 
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in both the wild-type and APOBEC1-deficient samples were compared and those 
editing events that also occurred in the knock-out sample were removed.  
 
5.1.7. Designation of single-site editing vs. hyper-editing 
 Initially some transcripts were identified to have numerous C-to-T 
changes at high frequency throughout the transcript 3’UTRs. However, some 
single high-frequency events were also associated with numerous low frequency 
events, comparable to the “ hyper-editing” noticed in enterocyte 3’UTR editing. 
From this, it was concluded that APOBEC1 editing is always associated with a 
few up- and down-stream editing events. To differentiate between true hyper-
edited and this associated editing, a set of hyper-editing rules were established.  
Transcripts with 3 or more high-confidence, high-frequency C-to-T changes 
(editing frequency ≥ 20%) or 2 high-frequency editing events and 3 or more 
moderate frequency events (editing fraction ≥ 0.09 and ≤ 0.19) were established 
as “hyper-edited”. All the remaining events were characterized as single-site 
edited, even those with 2 editing events. These rules resulting in a few transcripts 
with 2 editing events being designated as hyper-edited and a few as single-site 
edited based on the nature of the surrounding editing events.  
 
5.1.8. Validation of Editing targets  
Putative APOBEC1 editing events were validated with standard Sanger 
sequencing and subclone sequencing of cDNA and gDNA. cDNA was prepared 
from total RNA using Superscript III (Invitrogen) and oligo-dT priming. For 
Sanger sequencing, 3′UTRs were amplified from cDNA and genomic DNA using 
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Pfu Turbo high-fidelity polymerase (Stratagene). Sequencing was performed by 
GENEWIZ, Inc.. For subclone sequencing, amplicons were cloned into a 
Strataclone Blunt cloning vector and transformation colonies were selected by 
blue/white screening with Xgal. Individual colonies were picked and screened 
by GENEWIZ, Inc. One editing event occurring in a coding region with the 
frequency of approximately 50%, was thrown out under the presumption it was 
a genomic SNP. This event is included in the false positive calculation.  
 
5.1.9. Analysis of additional features of APOBEC1 editing  
Mooring sequences was identified using a custom python script, using 
tools in BioPython. In this script, genomic sequences were extracted for the 25bp 
downstream of the edited cytosine. Sequences of negative transcripts were 
reverse transcribed. These 25bp sequences were scanned for a perfect mooring 
motif (WRAUYANUAU) or a motif with 1 deviation (nucleotide mismatch or 
deletion) or a motif with 2 deviations. Scoring system for the mooring motif was 
based on mooring sequence distance from the edited cytosine and the sequence 
fidelity of the motif itself. Scoring system was a scale of 0 (no mooring motif) to 
10 (perfect mooring motif): -1pt for 2 bases beyond 4-6nt, -2 points for every 
mismatch.  
Flanking nucleotide analysis was performed as follows: the genomic 
sequence composition of the 5 nucleotides up and downstream of each edited 
cytosine was determined and submitted to the logo generating program found at 
http://weblogo.berkeley.edu/logo.cgi (Kohli et al., 2010).  
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5.2. Materials and methods specific to the characterization of the consequences 
of mRNA transcript 3’UTR editing in BMDMs 
5.2.1. Conservation analysis 
The conservation of APOBEC1 edited regions was calculated using a 
custom python script and the shuffleBed operation of BEDtools (Quinlan and 
Hall, 2010). 68 101nt windows surrounding APOBEC1 editing events were 
defined. For transcripts with more than one editing event, the highest frequency 
event (as defined from RNA-Seq) was used to eliminate bias. ShuffleBed was 
used to create sets of 68 101nt windows at random locations in 3′UTR regions of 
the UCSC known genes. PhastCons scores were obtained from the 
multialignment of mouse and 19 other placental mammals. The mean phastCon 
score for APOBEC1-edited windows and 100 random sets of 101nt windows was 
computed. If the window had no assigned PhastCon scores, it was thrown out. 
Based on this strategy, one edited window was eliminated from analysis. The 
mean phastCon score for 67 edit-containing windows was 0.47. The mean score 
for the random sets was never > 0.47, therefore we report a p value of < 0.01. 
Conservation analysis was performed with Python coding assistance from Eric 
Fritz, Papavasiliou lab.  
 
5.2.2. RNA-Seq transcript expression profiling  
Using aligned RNA-Seq data, transcript expression levels were calculated 
using the cuffdiff tool in the Cufflinks (v1.2.1) software package (Trapnell et al., 
2013) based on the Ensembl gene set.  
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5.2.3. Cloning dual-luciferase vectors  
For random cDNA cloning analysis: a series of edited and unedited 3′UTRs were 
amplified using a high-fidelity Pfu Turbo polymerase (Invitrogen) from wild-
type (“edited”) and Apobec1-/- (“unedited”) macrophage cDNA (cDNA was 
generated as descried in 5.1.2) and sub-cloned (Strataclone Blunt PCR cloning 
kit). Clones were sequenced (GENEWIZ) and representative clones for each 
degree of editing (single-site, number of hyper-edited events etc.) were inserted 
downstream of Firefly luciferase in a dual-luciferase vector (Promega pmirGLO 
dual-expression luciferase vector).  
 
For targeted miRNA analysis: “Un-edited” target 3’UTRs were amplified and 
cloned as described above. Site-specific mutagenesis was performed on unedited 
target 3′UTRs. Mutagenesis primers were designed using online tools provided 
by Agilent technologies (www.genomics.agilent.com). Mutated constructs were 
amplified with Pfu Turbo (Invitrogen) polymerase in the presence of 
mutagenesis primers followed by digestion with DpnI (New England Biolabs).  
 
5.2.4. Luciferase reporter assays 
Apobec1-/- BMDMs were transfected with dual-luciferase constructs and 
pmaxGFP transfection control vector using the Amaxa Mouse Macrophage 
Nucleofactor kit (Lonza). Renilla luciferase served as an internal control. Cells 
were incubated for 24 hours, lysed with passive lysis buffer by shaking at RT for 
15min and subjected to one freeze-thaw cycle at -80°C. Firefly and Renilla 
luciferase expression were measured using the dual-luciferase reporter system 
(Promega) and a FLUOstar Omega plate reader. Background luciferase levels 
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(pmaxGFP) were subtracted from experimental samples. Firefly expression was 
normalized to Renilla for each construct. Then, luciferase values measured for 
each “edited” construct was normalized to its “unedited” counterpart for 
graphical visualization. Significance for the difference between each “edited” 
and “unedited” pair was determined through a Student’s t-test (Excel).  
 
5.2.5. Immunoblotting 
 BMDMs were lysed in RIPA buffer (50mM Tris pH 8, 150mM NaCl, 0.5% 
deoxycholate, 0.1% SDS, 1% NP-40, 1mM DTT, protease inhibitor cocktail, 
0.5mM PMSF) on ice for 20 min. Protein concentrations were determined via 
Lowry assay (BioRad) and normalized lysates were run on pre-cast protein gels 
(BioRad Criterion, Tris-HCl) in running buffer (25mM Tris, 192mM glycine, 0.1% 
SDS). Proteins were transferred onto a nitrocellulose membrane by semi-dry 
transfer in transfer buffer (25mM Tris, 192mM glycine, 0.1% SDS, 20% methanol). 
Membranes were blocked in 5% milk in TBS-T and incubated with primary 
antibodies: App (clone 22C11, Millipore), B2m (Abcam), tubulin (Sigma, clone 
DM1A).  
 
5.2.6. Flow cytometry  
 BMDMs were removed from 10cm dishes by scraping or vigorous 
pipetting and pelleted by centrifugation (1000xg, 3 min). Cells were incubated 
with an Fc-receptor blocking antibody (BD Biosciences) for 10min at 4°C.  
 
For the staining of cell-surface markers: BMDMs were then incubated with the 
following fluorophore-conjugated primary antibodies:  
130
	   	  
1) Macrophage-specific cell surface markers: F4/80 (conjugated to AF-
488, Invitrogen), Cd11b (conjugated to PE, BD biosciences).  
2) Live:dead stain: 7AAD (BD Biosciences)  
3) CD36 antibody conjugated to APC; isotype control conjugated to APC 
(BD biosciences)  
For the staining of intracellular proteins: BMDMs were fixed and permeabilized 
according to parameters defined in the Cytofix/Cytoperm kit (BD biosciences). 
Lamp1 antibodies were conjugated to FITC and compared to a FITC isotype 
control (BD biosciences). No live/dead staining was used and the same Cd11b-
PE antibody from above and a comparable F4/80 conjugated to APC were used 
to isolate macrophages.  
 
5.2.7. FACS  
 BMDMs were stained for F4/80, Cd11b and CD36 as described above. 
Cells were sorted using a BD-FACS Aria machine for the top ~10% and bottom 
~10% cells expressing CD36. RNA was extracted, reverse transcribed, PCR 
amplified with CD36 specific primers and subjected to subclone sequencing as 
previously described.  
  
5.2.8. HTS-CLIP protocol  
HTS-CLIP analysis was performed as previously described (Chi et al., 
2009) with a few alterations. HITS-CLIP sample preparation was performed by 
Dr. Emily Conn Gantman in the Darnell lab. A brief summary of the CLIP 
protocol adapted from materials provided by Dr. Conn Gantman is described 
below. 
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BMDMs were prepared from 3 wild-type and APOBEC1-/- littermate pairs. 
BMDMs were matured as described above and crosslinked 3x at 200mJ/cm2 on 
the original maturation plates in 3mL of 1xPBS on a bed of ice. BMDMs were 
scrapped off the plates, flash-frozen and stored at -80C. Frozen cells were thawed 
and lysed in 1mL PXL lysis buffer (1x PBS, 0.1% SDS, 0.5% Na-DOC, 0.5% NP-40) 
with complete protease inhibitor. After lysing on ice with occasional vortexing, 
the cells were subjected to DNAse treatment with RQ1 RNAse-free DNAse 
(Promega) for 5 minutes at 37°C shaking in a Thermomixer. RNAse treatment 
performed with high (1:100) or low (1:10,000) RNAse A solutions and incubated 
for 5 minutes shaking at 37°C. Lysates were spun down (14,000RPM, 30minutes 
at 4°C) and the supernatant transferred to a new tube.  
Protein A beads were pre-loaded with rabbit anti-mouse IgG bridging 
antibody (Jackson ImmunoResearch, at 2.3 mg/mL), incubated for 35 minutes at 
room temperature. Beads were washed (in 0.02% Tween) and then loaded with 3 
uL Ago antibody (2A8 ascites provided by Dr. Zissimos Mourelatos- (Nelson et 
al., 2007)) per 400 uL of beads and rotated for 3 hours at 4°C. Cleared lysates 
were incubated with primary antibody-loaded beads for 2 hours at 4°C and 
washed in a series of washes: 1) 2x 1x PXL buffer; 2) 2x 5x PXL (5xPBS 0.1 % SDS, 
0.5% Na-DOC, 0.5% NP-40); 3) 2x with high stringency buffer (15mM Tris-HCl, 
pH 7.5, 5mM EDTA, 2.5mM EGTA, 1% Triton X-100, 1% Na-DOC, 0.1% SDS, 
120mM NaCl, 25mM KCl); 4) 1x with high salt buffer (15mM Tris-HCl, pH 7.5, 
5mM EDTA, 2.5mM EGTA, 1% Triton X-100, 1% Na-DOC, 0.1% SDS, 1M NaCl); 
5) 2x with low salt buffer (15mM Tris-HCl, pH 7.5, 5mM EDTA); 6) 2x NT-2 
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buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1mM MgCl2, 0.05% NP-40); 7) 2x 
PNK buffer (50mM Tris-HCl, pH 7.5, 10mM MgCl2, 0.5% NP-40).  
Dephosphorylation of the 5’ phosphate was performed with calf intestinal 
phosphatase (Roche) with RNAsin Plus RNAse Inhibitor (Promega) at 37°C for 
20 minutes, shaking at 1000rpm for 15s every 2 min. Beads were then washed 1) 
1x PNK buffer 2) 2x PNK buffer supplemented with 20mM EGTA 3) 2x PNK 
buffer.  
The puromycin blocked linker was radio-labeled with T4 PNK (New 
England Biolabs) and 32P-γ-ATP for 30 min at 37°C. Radiolabeled linker was spun 
through a G-25 column to remove free-ATP. Labeled 3’RNA linker was ligated to 
the 3’ end of the RNA with T4 RNA ligase (Fermentas) incubated at 16°C for 1 
hour, shaking at 1000rpm for 15s every 4 min. After 1 hour, 80 pmole of cold L32 
RNA linker with 5’ phosophate was added. Sampels were incubated overnight 
and washed 3x with PNK buffer. 5’ ends were re-phosphorylated with with T4 
PNK for 20 min at 37°C shaking at 1000rpm for 15s every 4 min.  
Protein:RNA complexes were eluted off the beads in NuPAGE loading 
buffer (Invitrogen) at 70°C for 10 min shaking at 1000rpm. Supernatants were 
run on Novex NuPAGE 8% Bis-Tris gels (Invitrogen) in MOPS running buffer 
(Invitrogen) for 2hr at 175V and transferred onto Protran BA85 nitrocellulose 
(Whatman) and exposed to Biomax MR film (Kodak).  
Regions that corresponded to Ago:mRNA and Ago:miRNA complexes 
were excised from the membrane (Figure 3.8A), diced and treated with 
proteinase K (4mg/mL Roche) for 20 min at 37°C shaking at 1100rpm. RNA was 
then extracted via phenol-chloroform extraction and ethanol precipitation. 5’ 
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linkers with a degenerate nucleotide end were ligated to the extracted RNA with 
T4 RNA ligase (Fermentas) at 16°C for 5 hours. The ligated reaction was then 
subjected to DNAse treatement with RQ1 DNAse (Promega) for 20min at 37°C 
and extracted with phenol-chloroform and subjected to ethanol precipitation.  
Precipitated RNA was reverse transcribed with Superscript III 
(Invitrogen) and PCR amplified with Accuprime Pfx Supermix (Invitrogen) for 
20-35 cycles. PCR products were run on a 10% denaturing polacrylamide gel and 
visualized with SYBR Gold (Molecular Probes) staining. 60-100nt products were 
excised from the lowest cycle number with visual product and gel extracted. 
Additional PCR amplification followed by gel extraction was performed as 
described with fusion primers to provide the platform for Illumina sequencing. 
10-30uL of 10nM DNA was submitted for sequencing on Illumina HiSeq.  
 
5.2.9. Processing and alignment of HITS-CLIP reads  
HITS-CLIP reads were filtered by quality (the first 5 nucleotides had a 
minimum quality score of 15 and the next 45 had a minimum mean score of 15) 
and exact sequences were collapsed. The 5’ linker was stripped off and Illumina 
adapter sequences were clipped from the 3’ end (Fastx Toolkit). Reads were then 
parsed by size into mRNA (≥25nt) and miRNA(≥ 17nt and ≤ 24nt) fractions using 
a custom python script. miRNA reads were aligned to mm9 using bowtie 
(v0.12.8) with the following specifications: “-l 17 -v 2 --best --strata -m 12”. To 
determine the best alignment strategy for his highly duplicated dataset we 
determined that the mmu-miRNAs mapped to a maximum of 12 separate 
genomic positions, so therefore we allowed up to 12 alignments per read. Read 
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counts were quantified with SeqMonk 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/) using 
miRNA intervals defined by miRBase (v18). miRNAs mapping to multiple 
positions in the genome were then collapsed.  
mRNA reads were uniquely aligned to mm9 using bowtie (v0.12.8) with 
the following options: “-v 2 --best --strata -m 1”. A second step of PCR duplicate 
removal was performed as previously described (Chi et al., 2012) in which reads 
with the same 5’ 5nt degenerate linker and the same coordinates were removed. 
This step eliminates true PCR duplicates, in which sequencing errors were also 
introduced, and would therefore be missed by an exact sequence collapser.  
 
5.2.10. Identifying Ago footprints 
Clusters were defined as regions with ≥ 8 reads that overlapped by at least 
5 nucleotides. The peaks of the clusters were identified as previously described 
(Chi et al., 2009). The “Ago footprint” around the cluster has been previously 
broadly defined as the region 32nt upstream and 30nt downstream from the peak 
(previously characterized in (Chi et al., 2009) as the region in which Ago in 
bound 95% of the time) or narrowly defined as the region 22nt upstream and 
24nt downstream (region in which Ago is bound 100% of the time). For this 
analysis, we identified APOBEC1:Ago overlap by looking at the broad definition 
of the footprint but identified potential miRNA target regions within the narrow 
footprint. The read depth of each footprint from HITS-CLIP and RNA-Seq was 
calculated using SeqMonk and CLIP depth was normalized to transcript 
expression (RNA-Seq read depth) to define the “Ago occupancy” (reads per 
million mapped CLIP/reads per million mapped RNA-Seq). This method should 
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provide accurate normalization, as it takes into account regions within each 
transcript that could be differentially expressed or differentially mapped, a 
phenomenon neglected when normalizing to total transcript expression. Ago 
footprints were filtered to 17,477 that were contained within “expressed” 
regions, defined as an RPM of greater than or equal to 1, as this provided 
reasonable coverage of these regions, and would eliminate the any problems 
with artifactually increasing Ago footprint occupancy values by normalizing to a 
value less than 1. The biological complexity (the number of replicates 
contributing to each Ago Footprint) was calculated based on the replicate 
contributing ≥2 reads to the footprint. “High-confidence” footprints (14,781) 
were defined as having a biological complexity of ≥ 2. As all APOBEC1 editing 
and most miRNA targeting happening within the 3′UTR of a given transcript, we 
narrowed our search to only 3′UTRs. We generated a permissive 3′UTR database 
from RefSeq by merging (Bedtools, mergeBed) overlapping 3′UTR regions, 
thereby defining a region as a 3′UTR if it was catalogued as such in any 
transcript isoform. 6,270 high-confidence footprints were contained within these 
merged 3′UTRs. To determine the additional genomic locations of footprints not 
located in 3’UTRs, a similar “merged” database of 5’UTRs and CDS were created. 
Footprints that do not occur in either 5’UTRs or CDS are listed as “other.”  
 
5.2.11 Identifying overlap between Ago and APOBEC1 targeting 
Overlap between Ago footprints and APOBEC1 editing was determined 
with the intersectBed function of Bedtools. The over-representation of APOBEC1 
editing events in CLIP footprints was calculated as follows. The fraction of the 
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total 3′UTR in which APOBEC1 editing could be identified (or “accessible 
3′UTRs”) was defined as regions of well-expressed 3′UTRs that were covered by 
≥ 20 reads. The number of nucleotides in the accessible 3′UTRs was calculated 
(A). The number of nucleotides in footprints that overlapped with accessible 
3′UTRs was also calculated (B). If we consider the number of editing events 
identified as C and the number of editing events within Ago footprints and D. 
Then the over-representation ratio of APOBEC1 editing events in footprints was 
calculated as (D/B)/(C/A). Odds ratio was calculated (D/B)/((C-D)/(A-B)) with 
significance and confidence intervals calculated in R.  
 
5.2.12 miRNA seed target search  
After the identification of high-confidence Ago footprints, we performed 
an exhaustive search to assign miRNA targets to those footprints and identify 
regions where APOBEC1 editing could create or destroy a miRNA target region. 
The search for miRNA target regions was performed with coding assistance from 
Dr. Dewi Harjanto, Papavasiliou lab. Using miRNA alignment data, we 
generated a list of bound miRNAs, defined as those that had a biological 
complexity of 3 in one of the two genotypes. Using a custom Python script, we 
scanned the footprint sequences for “canonical” matched miRNA 6mer seed 
regions (positions 2-7 of the mature miRNA sequence), as well as other non-
canonical matched 6mers from the 5’ end of the mature sequence (positions 1-6 
or 3-8). We also scanned the footprint sequences for “fuzzy” 6mers and 7mers (1 
nucleotide mismatch) and G-bulge seed regions (1 G insertion). Footprints were 
analyzed for the “best” miRNA target region fit, based on the sequence 
proximity to the footprint peak and the amount of the miRNA bound to Ago. We 
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identified a number of target regions that were either created or destroyed by 
APOBEC1 editing events and tested these with standard luciferase reporter assay 
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